<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cognitive behavioural therapy without medication for schizophrenia - Bighelli, I - 2024 | Cochrane Library</title> <meta content="Cognitive behavioural therapy without medication for schizophrenia - Bighelli, I - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015332.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cognitive behavioural therapy without medication for schizophrenia - Bighelli, I - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015332.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015332.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Cognitive behavioural therapy without medication for schizophrenia" name="citation_title"/> <meta content="Irene Bighelli&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="irene.bighelli@tum.de" name="citation_author_email"/> <meta content="Oğulcan Çıray&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Mardin State Hospital Child and Adolescent Psychiatry Department" name="citation_author_institution"/> <meta content="Nurul Husna Salahuddin" name="citation_author"/> <meta content="Technical University of Munich" name="citation_author_institution"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD015332.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/02/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015332.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015332.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015332.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antipsychotic Agents [therapeutic use]; *Cognitive Behavioral Therapy [methods]; Neoplasm Recurrence, Local [drug therapy]; Randomized Controlled Trials as Topic; *Schizophrenia [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015332.pub2&amp;doi=10.1002/14651858.CD015332.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015332\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015332\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","pt","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015332.pub2",title:"Cognitive behavioural therapy without medication for schizophrenia",firstPublishedDate:"Feb 7, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015332.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015332.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015332.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015332.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015332.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015332.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015332.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015332.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015332.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015332.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1891 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015332.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-sec-0223"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-sec-0105"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-sec-0217"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/supinfo/CD015332-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/supinfo/CD015332-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cognitive behavioural therapy without medication for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information#CD015332-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Irene Bighelli</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information#CD015332-cr-0005">Oğulcan Çıray</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information#CD015332-cr-0006">Nurul Husna Salahuddin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information#CD015332-cr-0007">Stefan Leucht</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information/en#CD015332-sec-0231">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 February 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015332.pub2">https://doi.org/10.1002/14651858.CD015332.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015332-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015332-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015332-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015332-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015332-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015332-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015332-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015332-abs-0001" lang="en"> <section id="CD015332-sec-0001"> <h3 class="title" id="CD015332-sec-0001">Background</h3> <p>Cognitive behavioural therapy (CBT) can be effective in people with schizophrenia when provided in combination with antipsychotic medication. It remains unclear whether CBT could be safely and effectively offered in the absence of concomitant antipsychotic therapy. </p> </section> <section id="CD015332-sec-0002"> <h3 class="title" id="CD015332-sec-0002">Objectives</h3> <p>To investigate the effects of CBT for schizophrenia when administered without concomitant pharmacological treatment with antipsychotics. </p> </section> <section id="CD015332-sec-0003"> <h3 class="title" id="CD015332-sec-0003">Search methods</h3> <p>We conducted a systematic search on 6 March 2022 in the Cochrane Schizophrenia Group's Study‐Based Register of Trials, which is based on CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, PubMed, ClinicalTrials.gov, and WHO ICTRP. </p> </section> <section id="CD015332-sec-0004"> <h3 class="title" id="CD015332-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) in people with schizophrenia comparing CBT without antipsychotics to standard care, standard care without antipsychotics, or the combination of CBT and antipsychotics. </p> </section> <section id="CD015332-sec-0005"> <h3 class="title" id="CD015332-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened references for inclusion, extracted data from eligible studies, and assessed risk of bias using Cochrane's RoB 2 tool. We contacted study authors for missing data and additional information. Our primary outcome was general mental state measured with a validated rating scale. Key secondary outcomes were specific symptoms of schizophrenia, relapse, service use, number of participants leaving the study early, functioning, quality of life, and number of participants actually receiving antipsychotics during the trial. We also assessed behaviour, adverse effects, and mortality. </p> </section> <section id="CD015332-sec-0006"> <h3 class="title" id="CD015332-sec-0006">Main results</h3> <p>We included 4 studies providing data for 300 participants (average age 21.94 years). The mean sample size was 75 participants (range 61 to 90 participants). Study duration was between 26 and 39 weeks for the intervention period and 26 to 104 weeks for the follow‐up period. Three studies employed a blind rater, while one study was triple‐blind. </p> <p>All analyses included data from a maximum of three studies. The certainty of the evidence was low or very low for all outcomes. </p> <p>For the primary outcome overall symptoms of schizophrenia, results showed a difference favouring CBT without antipsychotics when compared to no specific treatment at long term (&gt; 1 year mean difference measured with the Positive and Negative Syndrome Scale (PANSS MD) −14.77, 95% confidence interval (CI) −27.75 to −1.79, 1 RCT, n = 34). There was no difference between CBT without antipsychotics compared with antipsychotics (up to 12 months PANSS MD 3.38, 95% CI −2.38 to 9.14, 2 RCTs, n = 63) (very low‐certainty evidence) or compared with CBT in combination with antipsychotics (up to 12 months standardised mean difference (SMD) 0.30, 95% CI −0.06 to 0.65, 3 RCTs, n = 125). </p> <p>Compared with no specific treatment, CBT without antipsychotics was associated with a reduction in overall symptoms (as described above) and negative symptoms (PANSS negative MD −4.06, 95% CI −7.50 to −0.62, 1 RCT, n = 34) at longer than 12 months. It was also associated with a lower duration of hospital stay (number of days in hospital MD −22.45, 95% CI −28.82 to −16.08, 1 RCT, n = 74) and better functioning (Personal and Social Performance Scale MD −12.42, 95% CI −22.75 to −2.09, 1 RCT, n = 40, low‐certainty evidence) at up to 12 months. </p> <p>We did not find a difference between CBT and antipsychotics in any of the investigated outcomes, with the exception of adverse events measured with the Antipsychotic Non‐Neurological Side‐Effects Rating Scale (ANNSERS) at both 6 and 12 months (MD −4.94, 95% CI −8.60 to −1.28, 2 RCTs, n = 48; MD −6.96, 95% CI −11.55 to −2.37, 2 RCTs, n = 42). </p> <p>CBT without antipsychotics was less effective than CBT combined with antipsychotics in reducing positive symptoms at up to 12 months (SMD 0.40, 95% CI 0.05 to 0.76, 3 RCTs, n = 126). CBT without antipsychotics was associated with a lower number of participants experiencing at least one adverse event in comparison with CBT combined with antipsychotics at up to 12 months (risk ratio 0.36, 95% CI 0.17 to 0.80, 1 RCT, n = 39, low‐certainty evidence). </p> </section> <section id="CD015332-sec-0007"> <h3 class="title" id="CD015332-sec-0007">Authors' conclusions</h3> <p>This review is the first attempt to systematically synthesise the evidence about CBT delivered without medication to people with schizophrenia. The limited number of studies and low to very low certainty of the evidence prevented any strong conclusions. An important limitation in the available studies was that participants in the CBT without medication group (about 35% on average) received antipsychotic treatment, highlighting the challenges of this approach. Further high‐quality RCTs are needed to provide additional data on the feasibility and efficacy of CBT without antipsychotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015332-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015332-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015332-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015332-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015332-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015332-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015332-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015332-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015332-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015332-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015332-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015332-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015332-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015332-abs-0002" lang="en"> <h3>Cognitive behavioural therapy without antipsychotics for people with schizophrenia</h3> <p><b>Key messages</b> </p> <p>• There is not enough information to allow any strong conclusions about cognitive behavioural therapy (CBT) without medication for people with schizophrenia. </p> <p>• Additional studies are needed to look at the effectiveness and safety of CBT without medication for people with schizophrenia. </p> <p><b>Introduction</b> </p> <p>Schizophrenia is a severe mental disorder. People with the illness struggle to differentiate between their own thoughts, beliefs, and ideas versus reality. For example, they may hear voices in their head, but it feels like someone is really talking to them. CBT is a psychological intervention that can be effective for treating the symptoms of schizophrenia when it is offered with antipsychotic drugs. However, it remains unclear if CBT is effective and safe when used without these drugs. This is important to find out because the use of antipsychotics is often associated with unwanted side effects. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if CBT is effective and safe when used without medication for people with schizophrenia. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that examined CBT given without antipsychotics compared with no specific treatment, antipsychotics, or CBT plus antipsychotics. </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 4 studies that involved 300 participants with schizophrenia. Study duration was between 26 and 39 weeks for the intervention period, and participants were contacted again to collect further data between 26 and 104 weeks. The included studies were conducted in the UK and Australia, and were all sponsored by public institutions. </p> <p>We found that compared to no specific treatment, CBT without antipsychotics may result in a reduction in overall symptoms (at least in the long term) and negative symptoms (e.g. apathy, loss of interest and motivation, lack of concentration). It may also result in better functioning and lower duration of hospital stay in comparison with no specific treatment. </p> <p>CBT without antipsychotics may not differ from CBT plus antipsychotics in modifying overall symptoms of schizophrenia. CBT without antipsychotics may be less effective than CBT plus antipsychotics in reducing positive symptoms specifically (e.g. hearing voices), and may result in fewer adverse effects compared to CBT plus antipsychotics. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The certainty of the evidence was low to very low, meaning that we have limited to very little confidence in the results. This is because study participants and therapists were aware of the treatment being received, which could have influenced the results. In addition, it was often the case that during the study participants received treatment with antipsychotics when this was not planned. Furthermore, not all of the studies provided data about everything that we were interested in, and the numbers of included studies and study participants were too small to be certain about the results. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is current to March 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015332-sec-0223" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015332-sec-0223"></div> <h3 class="title" id="CD015332-sec-0224">Implications for practice</h3> <section id="CD015332-sec-0224"> <p>Based on limited and very low‐certainty evidence, offering cognitive behavioural therapy (CBT) without antipsychotics was not associated with a worsening of symptoms or increased hospital admissions. We also found that the combination of CBT with antipsychotics might be beneficial for some outcomes compared to CBT alone. </p> <p>An interpretation of the results for the practice is difficult because the results are to some degree conflicting: on the one hand, adding antipsychotics to CBT helps, as shown by results of comparison 3, where CBT was less efficacious than CBT plus antipsychotics. On the other hand, when compared directly in comparison 2, CBT and antipsychotics did not show a difference in efficacy. </p> <p>Moreover, to date only two working groups have attempted to conduct clinical trials in which a group of participants with schizophrenia was randomised to not receive antipsychotic medication. These studies have investigated selected subpopulations of participants (people refusing to take antipsychotics, people with a first episode; see <a href="#CD015332-sec-0219">Overall completeness and applicability of evidence</a>). On average, participants were found to be only moderately ill at baseline, thus the findings may not be generalisable to the more severely ill participants. For all of these reasons, the results should be interpreted cautiously and can hardly be generalised to the general population of people with schizophrenia. It must also be noted that a substantial proportion of participants in the included studies ultimately needed antipsychotics, and this might also be the case in clinical practice. </p> <p>The information in this review can be used in the context of a shared decision‐making process to make informed decisions about the individual clinical plan. </p> </section> <h3 class="title" id="CD015332-sec-0225">Implications for research</h3> <section id="CD015332-sec-0225"> <p>As highlighted above, one of the major limitations of the current evidence was the limited number of studies and participants. </p> <p>A large, final, and high‐quality randomised trial, employing blind raters and adopting an intention‐to‐treat analysis approach, is warranted. This study should be appropriately funded and have resources in order to be adequately powered to detect feasibility and efficacy. </p> <p>In particular, attempts could be made to recruit participants not only at the early stage of the disorder, but also in the later phases, and eventually also the more severely ill. </p> <p>The current results show that such investigations might be safe (no worsening of symptoms or relapses detected); however, the high number of participants that received antipsychotic treatment during the trial against randomisation show that feasibility issues exist (<a href="#CD015332-tbl-0004">Table 1</a>). </p> <p>It would also be useful if new randomised trials offering CBT in addition to standard care strictly monitor and provide detailed information about the type and dose of antipsychotics received by participants so that the role of the medication can be investigated in the analyses. </p> <p>Finally, the analysis of data at a patient level with an individual patient data meta‐analysis approach would allow a detailed investigation of the individual characteristics of the participants and determine for which people CBT without antipsychotics may be feasible or efficacious, or both. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015332-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015332-sec-0008"></div> <div class="table" id="CD015332-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to no specific treatment for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBT without antipsychotics compared to no specific treatment for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> <br/><b>Intervention:</b> CBT without antipsychotics<br/><b>Comparison:</b> no specific treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no specific treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT without antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ general: mean endpoint PANSS total (high = poor) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>9.77 lower</b><br/>(20.59 lower to 1.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ &gt; 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(3 to 285) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.05 to 5.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/>(31 to 372) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.23 to 2.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functioning ‐ mean endpoint PSP (high = good) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>12.42 lower</b><br/>(22.75 lower to 2.09 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Participants with at least one AE ‐ &gt; 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_439003076253823530" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_439003076253823530</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI includes both better outcome for CBT without antipsychotics and almost no difference<br/><sup>b</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) and CI includes both better outcome for CBT without antipsychotics and better outcome for standard care without antipsychotics </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015332-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBT without antipsychotics compared to antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> <br/><b>Intervention:</b> CBT without antipsychotics<br/><b>Comparison:</b> antipsychotics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antipsychotics</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT without antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ general: mean endpoint PANSS total (high = poor) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>3.38 higher</b><br/>(2.38 lower to 9.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.78</b><br/>(0.12 to 65.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/>(5 to 281) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.66</b><br/>(0.21 to 12.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functioning ‐ mean endpoint functioning scales (high = good) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.03 lower</b><br/>(0.61 lower to 0.55 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Participants with at least one AE (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>591 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b><br/>(124 to 632) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b><br/>(0.21 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842958834426261" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842958834426261</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for risk of bias: two out of two studies were at overall high risk of bias<br/><sup>b</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI includes both better outcome for CBT without antipsychotics and better outcome for standard care<br/><sup>c</sup> Downgraded by two levels for risk of bias: one out of one study was at overall high risk of bias<br/><sup>d</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) and CI includes both better outcome for CBT without antipsychotics and better outcome for standard care<br/><sup>e</sup> Downgraded by one level for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015332-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to CBT plus antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBT without antipsychotics compared to CBT plus antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> <br/><b>Intervention:</b> CBT without antipsychotics<br/><b>Comparison:</b> CBT plus antipsychotics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT plus antipsychotics</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT without antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.3 higher</b><br/>(0.06 lower to 0.65 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.89</b><br/>(0.12 to 67.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/>(8 to 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b><br/>(0.12 to 4.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functioning ‐ mean endpoint functioning scales (high = good) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.13 higher</b><br/>(0.25 lower to 0.5 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Participants with at least one AE (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b><br/>(130 to 610) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b><br/>(0.17 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842947953353100" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842947953353100</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for risk of bias: two out of three studies were at overall high risk of bias<br/><sup>b</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI includes both no difference and better outcome for CBT plus antipsychotics<br/><sup>c</sup> Downgraded by two levels for risk of bias: one out of one study was at overall high risk of bias<br/><sup>d</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) and CI includes both no difference and better outcome for CBT plus antipsychotics<br/><sup>e</sup> Downgraded by two levels for risk of bias: two out of two studies were at overall high risk of bias<br/><sup>f</sup> Downgraded by one level for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome)<br/><sup>g</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI ranges from better outcome with CBT without antipsychotics to better outcome with CBT plus antipsychotics<br/><sup>h</sup> Downgraded by one level for risk of bias: the study is at overall high risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015332-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015332-sec-0009"></div> <p>Schizophrenia is a chronic and severe psychiatric disorder seen in approximately 1% of the population and which causes significant functional loss (<a href="./references#CD015332-bbs2-0057" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Schizophrenia Bulletin2008;30(1):67-76.">McGrath 2008</a>). </p> <p>Antipsychotic drugs are effective for the acute treatment and relapse prevention of the disorder (<a href="./references#CD015332-bbs2-0036" title="HuhnM , NikolakopoulouA , Schneider-ThomaJ , KrauseM , SamaraM , PeterN , et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet2019;394:939-51. [DOI: 10.1016/S0140-6736(19)31135-3]">Huhn 2019</a>; <a href="./references#CD015332-bbs2-0072" title="Schneider-ThomaJ , ChalkouK , DörriesC , BighelliI , CerasoA , HuhnM , et al. Comparative efficacy and tolerability of 31 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet2022;399(10327):824-36. [DOI: 10.1016/S0140-6736(21)01997-8]">Schneider‐Thoma 2022</a>), but are associated with burdensome side effects that are likely to contribute to excess mortality associated with the disorder (<a href="./references#CD015332-bbs2-0035" title="HjorthøjC , StürupAE , McGrathJJ , NordentoftM . Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry2017;4:295-301.">Hjorthøj 2017</a>). </p> <p>Psychotherapeutic interventions for schizophrenia have been developed to address the various aspects of the disorder and are widely recommended in accordance with the guidelines of the National Institute for Health and Care Excellence (NICE) (<a href="./references#CD015332-bbs2-0066" title="National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. www.nice.org.uk/guidance/cg178/chapter/1-Recommendations (accessed prior to 13 June 2022).">NICE 2014</a>). These interventions are usually offered in combination with antipsychotic medications, so that the separate roles of psychological and of pharmacological treatment cannot be ascertained so far (<a href="./references#CD015332-bbs2-0015" title="BighelliI , LeuchtC , HuhnM , ReitmeirC , SchwermannF , WallisS , et al. Are randomized controlled trials on pharmacotherapy and psychotherapy for positive symptoms of schizophrenia comparable? A systematic review of patient and study characteristics. Schizophrenia Bulletin2020;46(3):496-504. [DOI: 10.1093/schbul/sbz090]">Bighelli 2020</a>). </p> <p>There exist studies that have attempted to provide psychotherapy with cognitive behavioural therapy (CBT) to participants that were not receiving antipsychotic medication (<a href="./references#CD015332-bbs2-0061" title="MorrisonAP , HuttonP , ShiersD , TurkingtonD . Antipsychotics: is it time to introduce patient choice?British Journal of Psychiatry2012;201:83-4. [DOI: 10.1192/bjp.bp.112.112110]">Morrison 2012a</a>; <a href="./references#CD015332-bbs2-0063" title="MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383:1395-403. [DOI: 10.1016/S0140-6736(13)62246-1]">Morrison 2014</a>). These studies could be an opportunity to determine the role of psychotherapy alone in improving the symptoms of schizophrenia. </p> <p>We planned in this Cochrane review to summarise all randomised controlled trials that investigated CBT provided without concomitant antipsychotic medication compared to the combination of CBT and medication, medication alone, or no specific treatment. </p> <section id="CD015332-sec-0010"> <h3 class="title" id="CD015332-sec-0010">Description of the condition</h3> <p>Schizophrenia is a chronic and severe psychiatric disorder affecting approximately 1% of the population worldwide (<a href="./references#CD015332-bbs2-0057" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Schizophrenia Bulletin2008;30(1):67-76.">McGrath 2008</a>). Onset typically occurs in the second decade of life (<a href="./references#CD015332-bbs2-0043" title="KirkbrideJB , HameedY , AnkireddypalliG , IoannidisK , CraneCM , NasirM , et al. The epidemiology of first-episode psychosis in early intervention in psychosis services: findings from the Social Epidemiology of Psychoses in East Anglia [SEPEA] study. American Journal of Psychiatry2017;174:143-53.">Kirkbride 2017</a>), and usually has a significant impact in terms of quality of life, functioning, social inclusion, and disability. According to the Global Burden of Disease Study 2019, schizophrenia is ranked 9th in terms of years lived with disability (YLDs) in the age range 15 to 49 years (<a href="./references#CD015332-bbs2-0028" title="Global Burden of Diseases 2019. http://www.healthdata.org/gbd/gbd-2019-resources.">GBD 2019</a>). </p> <p>Typical symptom manifestations of the condition include severe thought disturbances, which may lead to delusions (beliefs that are not based on reality) and hallucinations, for example hearing or seeing things that are not there. These manifestations are usually defined as 'positive' symptoms, because they are unusual by their presence. By contrast, 'negative' symptoms are unusual by their absence, and can include a restricted range and intensity of emotional expression and a reduced ability to experience pleasure. </p> <p>Difficulties with concentration, attention, and motivation may also lead to reduced participation in or abandoning education activities and reduced employment; it is estimated that up to 80% of people with schizophrenia are not employed (<a href="./references#CD015332-bbs2-0055" title="MarwahaS , JohnsonS . Schizophrenia and employment – a review. Social Psychiatry and Psychiatric Epidemiology2004;39(5):337-49. [DOI: 10.1007/s00127-004-0762-4]">Marwaha 2004</a>). </p> <p>Different stages can be identified in the course of the disease. In the onset or prodromal phase, subtle modifications in the person's behaviour, cognition, and feelings can be identified, which then develop into clear psychotic symptoms during the acute phase. After the acute episode, florid symptoms recede during the remission phase (<a href="./references#CD015332-bbs2-0010" title="AndreasenN , CarpenterW , KaneJ , LasserR , MarderS , WeinbergerD . Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry2005;62:441-9. [PMID: 15741458]">Andreasen 2005</a>). In this stage, most individuals still require maintenance treatment in order to prevent symptoms recrudescence (relapse). </p> </section> <section id="CD015332-sec-0011"> <h3 class="title" id="CD015332-sec-0011">Description of the intervention</h3> <p>Antipsychotic medication is the current first‐line treatment for schizophrenia. Due to the chronic nature of the disease, long‐term treatment with antipsychotics is usually needed to prevent the risk of relapse (<a href="./references#CD015332-bbs2-0018" title="CerasoA , LinJJ , Schneider-ThomaJ , SiafisS , TardyM , KomossaK , et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2020, Issue 8. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub3]">Ceraso 2020</a>; <a href="./references#CD015332-bbs2-0072" title="Schneider-ThomaJ , ChalkouK , DörriesC , BighelliI , CerasoA , HuhnM , et al. Comparative efficacy and tolerability of 31 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet2022;399(10327):824-36. [DOI: 10.1016/S0140-6736(21)01997-8]">Schneider‐Thoma 2022</a>). Unfortunately, these medications have many adverse events that make their use complicated, including movement disorders, weight gain, metabolic problems, and sexual dysfunction (<a href="./references#CD015332-bbs2-0052" title="LeuchtS , CiprianiA , SpineliL , MavridisD , OreyD , RichterF . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet2013;382:951-62. [DOI: 10.1016/S0140-6736(13)60733-3]">Leucht 2013</a>; <a href="./references#CD015332-bbs2-0071" title="Schneider-ThomaJ , EfthimiouO , BighelliI , DörriesC , HuhnM , KrauseM , et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry2019;6(9):753-65. [DOI: 10.1016/S2215-0366(19)30223-8]">Schneider‐Thoma 2019</a>). Also, for this reason, people with schizophrenia are often ambivalent about taking medications, and rates of medication non‐compliance are high (<a href="./references#CD015332-bbs2-0044" title="LacroJP , DunnLB , DolderCR , LeckbandSG , JesteDV . Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry2002;63:892-909. [DOI: 10.4088/jcp.v63n1007]">Lacro 2002</a>; <a href="./references#CD015332-bbs2-0058" title="MoncrieﬀJ , CohenD , MasonJP . The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatrica Scandinavica2009;120:102-11. [DOI: 10.1111/j.1600-0447.2009.01356.x]">Moncrieff 2009</a>). Moreover, recent guidelines tend to shift their recommendations from not recommending to partially recommending antipsychotic discontinuation, both for schizophrenia in general and for first‐episode schizophrenia (<a href="./references#CD015332-bbs2-0074" title="ShimomuraY , KikuchiY , SuzukiT , UchidaH , MimuraM , TakeuchiH . Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophrenia Research2020;215:8-16. [DOI: 10.1016/j.schres.2019.09.013]">Shimomura 2020</a>). </p> <p>Some authors have argued that the efficacy of antipsychotics may have been overestimated, and their adverse effects underestimated, suggesting that clinicians reconsider “whether everyone who meets the criteria for a schizophrenia spectrum diagnosis requires antipsychotics in order to recover" (<a href="./references#CD015332-bbs2-0061" title="MorrisonAP , HuttonP , ShiersD , TurkingtonD . Antipsychotics: is it time to introduce patient choice?British Journal of Psychiatry2012;201:83-4. [DOI: 10.1192/bjp.bp.112.112110]">Morrison 2012a</a>). </p> <p>Cognitive behavioural therapy (CBT) is a psychological intervention developed by Aaron Beck in 1979 to be used in the treatment of depression (<a href="./references#CD015332-bbs2-0013" title="Beck AT (editor). Cognitive Therapy of Depression. Guilford Press, 1979.">Beck 1979</a>). The aims of CBT are to establish links between the person's thoughts, feelings, or actions with respect to current or past symptoms and/or functioning; individuals are encouraged to re‐evaluate their perceptions, beliefs, or reasoning in relation to the target symptoms. Alternative ways of coping with the target symptom can be promoted, with the aim of reducing stress and improving functioning (<a href="./references#CD015332-bbs2-0066" title="National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. www.nice.org.uk/guidance/cg178/chapter/1-Recommendations (accessed prior to 13 June 2022).">NICE 2014</a>). </p> <p>CBT began to be used for schizophrenia in the late 1980s and early 1990s (<a href="./references#CD015332-bbs2-0042" title="KingdonD , TurkingtonD . Cognitive behaviour therapy of schizophrenia. In: WykesT , TarrierN , LewisS , editors(s). Outcome and Innovation in Psychological Treatment of Schizophrenia. John Wiley &amp; Sons Inc, 1998:59-79.">Kingdon 1998</a>). CBT for psychosis (CBTp) is a problem‐centred, structured type of therapy based on patient‐clinician collaboration. It was developed with the primary aim of reducing symptom severity, and there is evidence that it may be effective in this regard when used in addition to antipsychotic medication (<a href="./references#CD015332-bbs2-0014" title="BighelliI , SalantiG , HuhnM , Schneider-ThomaJ , KrauseM , ReitmeirC , et al. Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. World Psychiatry2018;17(3):316-29.">Bighelli 2018</a>; <a href="./references#CD015332-bbs2-0038" title="JauharS , McKennaPJ , RaduaJ , FungE , SalvadorR , LawsKR . Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry2014;204:20-9. [DOI: 10.1192/bjp.bp.112.116285]">Jauhar 2014</a>; <a href="./references#CD015332-bbs2-0039" title="JonesC , HackerD , MeadenA , CormacI , IrvingCB , XiaJ , et al. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD008712. [DOI: 10.1002/14651858.CD008712.pub3]">Jones 2018a</a>; <a href="./references#CD015332-bbs2-0040" title="JonesC , HackerD , XiaJ , MeadenA , IrvingCB , ZhaoS , et al. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD007964. [DOI: 10.1002/14651858.CD007964.pub2]">Jones 2018b</a>; <a href="./references#CD015332-bbs2-0080" title="WykesT , SteelC , EverittB , TarrierN . Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophrenia Bulletin2008;34(3):523-37. [DOI: 10.1093/schbul/sbm114]">Wykes 2008</a>; <a href="./references#CD015332-bbs2-0083" title="ZimmermannG , FavrodJ , TrieuVH , PominiV . The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophrenia Research2005;77:1-9.">Zimmermann 2005</a>). There is evidence that CBT could also be beneficial for improving other outcomes in people with schizophrenia, such as insight, well‐being, and functioning (<a href="./references#CD015332-bbs2-0039" title="JonesC , HackerD , MeadenA , CormacI , IrvingCB , XiaJ , et al. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD008712. [DOI: 10.1002/14651858.CD008712.pub3]">Jones 2018a</a>; <a href="./references#CD015332-bbs2-0045" title="LawsKR , DarlingtonN , KondelTK , McKennaPJ , JauharS . Cognitive behavioural therapy for schizophrenia – outcomes for functioning, distress and quality of life: a meta-analysis. BMC Psychology2018;6(1):32. [DOI: 10.1186/s40359-018-0243-2]">Laws 2018</a>). Based on this literature, current guidelines recommend offering CBT in addition to pharmacological treatment with antipsychotics (<a href="./references#CD015332-bbs2-0066" title="National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. www.nice.org.uk/guidance/cg178/chapter/1-Recommendations (accessed prior to 13 June 2022).">NICE 2014</a>). </p> <p>However, in all existing meta‐analyses, CBT was investigated as provided in combination with antipsychotics (<a href="./references#CD015332-bbs2-0038" title="JauharS , McKennaPJ , RaduaJ , FungE , SalvadorR , LawsKR . Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry2014;204:20-9. [DOI: 10.1192/bjp.bp.112.116285]">Jauhar 2014</a>; <a href="./references#CD015332-bbs2-0039" title="JonesC , HackerD , MeadenA , CormacI , IrvingCB , XiaJ , et al. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD008712. [DOI: 10.1002/14651858.CD008712.pub3]">Jones 2018a</a>; <a href="./references#CD015332-bbs2-0040" title="JonesC , HackerD , XiaJ , MeadenA , IrvingCB , ZhaoS , et al. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD007964. [DOI: 10.1002/14651858.CD007964.pub2]">Jones 2018b</a>; <a href="./references#CD015332-bbs2-0080" title="WykesT , SteelC , EverittB , TarrierN . Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophrenia Bulletin2008;34(3):523-37. [DOI: 10.1093/schbul/sbm114]">Wykes 2008</a>; <a href="./references#CD015332-bbs2-0083" title="ZimmermannG , FavrodJ , TrieuVH , PominiV . The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophrenia Research2005;77:1-9.">Zimmermann 2005</a>). As a result, the role of CBT without concomitant antipsychotic treatment is unclear. </p> <p>NICE guidelines for children and adolescents with a first episode of psychosis include the possibility of offering family intervention with individual CBT to young people with schizophrenia and their carers, if they wish to try psychological interventions alone (<a href="./references#CD015332-bbs2-0065" title="National Institute for Clinical Excellence. Psychosis and schizophrenia in children and young people: Recognition and management. www.nice.org.uk/guidance/cg155/resources/psychosis-and-schizophrenia-in-children-and-young-people-recognition-and-management-pdf-351096329809332013.">NICE 2013</a>). As emphasised in the guidelines, such an approach requires strict and regular monitoring of the symptoms, distress, and functioning. </p> <p>In recent years, there have been attempts to deliver CBT alone to people with schizophrenia (<a href="./references#CD015332-bbs2-0061" title="MorrisonAP , HuttonP , ShiersD , TurkingtonD . Antipsychotics: is it time to introduce patient choice?British Journal of Psychiatry2012;201:83-4. [DOI: 10.1192/bjp.bp.112.112110]">Morrison 2012a</a>; <a href="./references#CD015332-bbs2-0063" title="MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383:1395-403. [DOI: 10.1016/S0140-6736(13)62246-1]">Morrison 2014</a>). These attempts have raised criticism and ethical concerns (<a href="./references#CD015332-bbs2-0064" title="MustafaFA . Stand-alone cognitive behavioural therapy is not in clinical equipoise with antipsychotic treatment. Lancet Psychiatry2018;5(7):540. [DOI: 10.1016/S2215-0366(18)301639]">Mustafa 2018</a>), but also opened the way to new research and clinical perspectives. </p> </section> <section id="CD015332-sec-0012"> <h3 class="title" id="CD015332-sec-0012">How the intervention might work</h3> <p>CBT encourages the person to establish links between their thoughts, feelings, or behaviours with respect to their symptoms. The aim of creating these connections is to change the way in which the individual interprets and evaluates their experiences and attributes meaning to them. </p> <p>By helping people recognise their basic feelings, thoughts, and behaviours about the disease, CBT can improve the ability of people with schizophrenia to cope with their psychotic symptoms and can be an important and helpful tool (<a href="./references#CD015332-bbs2-0060" title="MorrisonA , BarrattS . What are the components of CBT for psychosis? A Delphi study. Schizophrenia Bulletin2010;36(1):136-42. [DOI: 10.1093/schbul/sbp118]">Morrison 2010</a>). Being able to recognise inappropriate thoughts, feelings, and behaviours can reduce people's stress burden, improve their quality of life, and help recovery (<a href="./references#CD015332-bbs2-0060" title="MorrisonA , BarrattS . What are the components of CBT for psychosis? A Delphi study. Schizophrenia Bulletin2010;36(1):136-42. [DOI: 10.1093/schbul/sbp118]">Morrison 2010</a>). </p> <p>Individuals are stimulated to identify and challenge biased interpretations of their experiences that may have a role in the continuation of symptoms. </p> </section> <section id="CD015332-sec-0013"> <h3 class="title" id="CD015332-sec-0013">Why it is important to do this review</h3> <p>A few attempts and clinical trials have been conducted on the administration of CBT without concomitant antipsychotic medication (<a href="./references#CD015332-bbs2-0061" title="MorrisonAP , HuttonP , ShiersD , TurkingtonD . Antipsychotics: is it time to introduce patient choice?British Journal of Psychiatry2012;201:83-4. [DOI: 10.1192/bjp.bp.112.112110]">Morrison 2012a</a>; <a href="./references#CD015332-bbs2-0063" title="MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383:1395-403. [DOI: 10.1016/S0140-6736(13)62246-1]">Morrison 2014</a>). However, this literature has never been systematically appraised, nor the results synthesised with a meta‐analysis. As a result, no evidence in the form of a systematic review exists on the effects of CBT when administered alone in people with schizophrenia. </p> <p>Evidence on this issue would be highly relevant for clinical practice.</p> <p>On the one hand, antipsychotics have burdensome side effects, therefore if it was proven that CBT is effective also without pharmacological treatment, this may reduce patient burden and costs related to the intervention. Nevertheless, the feasibility of such an option should be carefully examined, because not offering an antipsychotic medication goes against current clinical guidelines, and may be considered a critical ethical issue (<a href="./references#CD015332-bbs2-0064" title="MustafaFA . Stand-alone cognitive behavioural therapy is not in clinical equipoise with antipsychotic treatment. Lancet Psychiatry2018;5(7):540. [DOI: 10.1016/S2215-0366(18)301639]">Mustafa 2018</a>). On the other hand, the combination of the two interventions may increase the efficacy of the treatment in comparison to their stand‐alone use. </p> <p>The aim of this Cochrane review was to provide a comprehensive examination of the existing evidence on the feasibility and effectiveness of CBT offered without concomitant pharmacological therapy in people with schizophrenia, and help shed light on this challenging matter. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015332-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015332-sec-0014"></div> <p>To investigate the effects of CBT for schizophrenia when administered without concomitant pharmacological treatment with antipsychotics. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015332-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015332-sec-0015"></div> <section id="CD015332-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015332-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all relevant randomised controlled trials (RCTs). We included RCTs meeting our inclusion criteria and reporting useable data either for the qualitative or quantitative synthesis. Both open‐label and rater‐blind studies were eligible for inclusion in the review. We excluded quasi‐randomised studies, such as those that allocated intervention by alternate days of the week. Where people were given treatments in addition to CBT, we only included data if the adjunct treatment was evenly distributed between groups, and it was only the CBT that was randomised. </p> </section> <section id="CD015332-sec-0018"> <h4 class="title">Types of participants</h4> <p>People with schizophrenia, as defined in the included studies, or related disorders such as schizophreniform disorder, schizoaffective disorder and delusional disorder, by any means of diagnosis. We did not include trials where the majority of participants had such disorders as bipolar affective disorder or substance‐induced psychosis. </p> <p>If a study included participants with other diagnoses, we included the study only if participants with a diagnosis of schizophrenia or related disorders constituted at least 50% of the participants. </p> <p>We excluded trials where participants had organic psychoses, as well as studies that recruited participants with prodromal symptoms or at‐risk mental states. </p> <p>We wanted to ensure that the information was as relevant as possible to the current care of people with schizophrenia, and so aimed to highlight the current clinical state clearly (acute, early post‐acute, partial remission, remission) as well as the stage (first episode, early illness, chronic) and whether the studies focused primarily on people with particular problems (e.g. negative symptoms, treatment‐resistant illnesses). We planned to investigate the effect of the intervention on chronic patients and on people with a first episode of psychosis in a subgroup analysis (see <a href="#CD015332-sec-0087">Subgroup analysis and investigation of heterogeneity</a>). </p> <p>Where a study recruited participants from early intervention services without providing additional details about inclusion criteria, we evaluated on a case‐by‐case basis if the participants matched the characteristics of the population of the current review as described above, requesting additional details from the authors as necessary. </p> </section> <section id="CD015332-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD015332-sec-0020"> <h5 class="title">1. CBT without concomitant medication for schizophrenia</h5> <p>'Cognitive behavioural therapy' has been used as a broad label that can include a variety of interventions. It typically includes elements of cognitive restructuring or cognitive therapy (CT) and elements of behavioural therapy (BT) that are delivered together. However, CT and BT elements could also be approached separately in the therapeutic process. In this review, we considered any intervention that includes CT or BT elements alone, as well as CBT interventions that include both components, as eligible under the term 'CBT'. In this review, CBT was evaluated in people with schizophrenia who were not taking concurrent medication. </p> <p>The group that received structured CBT and did not receive antipsychotic treatment was used as the intervention group. For simplicity, we referred to this condition as 'CBT'. </p> </section> <section id="CD015332-sec-0021"> <h5 class="title">2. Control</h5> <p>We included any control condition applied in studies that aimed to investigate the effects of CBT without concomitant medication in people with schizophrenia. </p> <p>We classified the control condition as follows.</p> <section id="CD015332-sec-0022"> <h6 class="title">2.1 No specific treatment</h6> <p>Participants are randomised to receive standard care, explicitly excluding the prescription of an antipsychotic medication. The possibility of receiving rescue medication, if needed, was not excluded. For simplicity, we referred to this control condition as 'No specific treatment'. </p> </section> <section id="CD015332-sec-0023"> <h6 class="title">2.2 Antipsychotics</h6> <p>Participants are randomised to standard care, which normally includes antipsychotics; participants in this group may have received some form of psychosocial support, but not CBT. For simplicity, we referred to this control condition as 'Antipsychotics', abbreviated 'AP' in the forest plots. </p> </section> <section id="CD015332-sec-0024"> <h6 class="title">2.3 CBT in combination with antipsychotics</h6> <p>Participants are randomised to receive CBT in addition to standard care, which usually includes antipsychotics. No distinction will be made between antipsychotics (e.g. first or second generation), doses, or administration forms (oral, injection), and all will be included. For simplicity, we referred to this control condition as 'CBT plus antipsychotics', abbreviated 'CBT + AP' in the forest plots. </p> </section> </section> </section> <section id="CD015332-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>We aimed to divide all outcomes into short term (up to 6 months since the onset of therapy), medium term (up to 12 months), and long term (over 12 months). This grouping reflects NICE recommendations that CBT should be delivered for at least 16 sessions (<a href="./references#CD015332-bbs2-0066" title="National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. www.nice.org.uk/guidance/cg178/chapter/1-Recommendations (accessed prior to 13 June 2022).">NICE 2014</a>). </p> <p>For outcomes such as 'clinically important change', 'any change', and 'relapse', we used the definitions reported in the included trials. </p> <p>For valid scales, see <a href="#CD015332-sec-0053">Data extraction and management</a>. </p> <section id="CD015332-sec-0026"> <h5 class="title">Primary outcomes</h5> <section id="CD015332-sec-0027"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0028"> <p><b>1.1 General</b></p> <p>1.1.1 Average endpoint or change score on a general mental state scale (e.g. Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS)) </p> </section> </section> </section> <section id="CD015332-sec-0029"> <h5 class="title">Secondary outcomes</h5> <section id="CD015332-sec-0030"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0031"> <p><b>1.1 General</b></p> <p>1.1.1 Clinically important change in general mental state (study defined)</p> </section> <section id="CD015332-sec-0032"> <p><b>1.2 Specific</b></p> <p>1.2.1 Clinically important change in positive symptoms (delusions, hallucinations, disordered thinking), as defined by individual studies </p> <p>1.2.2 Average endpoint or change score on a published scale/subscale addressing positive symptoms (e.g. PANSS positive, PANSS positive factor, Scale for the Assessment of Positive Symptoms (SAPS)) </p> <p>1.2.3 Clinically important change in negative symptoms (avolition, poor self‐care, blunted affect), as defined by individual studies </p> <p>1.2.4 Average endpoint or change score on a published scale/subscale addressing negative symptoms (e.g. PANSS negative, PANSS negative factor, Scale for the Assessment of Negative Symptoms (SANS)) </p> <p>1.2.5 Clinically important change in depressive symptoms, as defined by individual studies </p> <p>1.2.6 Average endpoint or change score on a published scale/subscale addressing depressive symptoms (e.g. Montgomery‐Asberg Depression Rating Scale (MADRS), Beck Depression Inventory (BDI)) </p> <p>1.2.7 Clinically important change in anxiety symptoms, as defined by individual studies</p> <p>1.2.8 Average endpoint or change score on a published scale/subscale addressing anxiety (e.g. Hamilton Anxiety Rating scale (HAM‐A) or Beck Anxiety Inventory (BAI)) </p> </section> </section> <section id="CD015332-sec-0033"> <h6 class="title">2. Global state</h6> <p>2.1 Relapse</p> <p>In case more measures of relapse were reported, we gave priority to: (i) relapse defined with operationalised criteria (e.g. worsening on a symptom scale); (ii) clinical judgement. </p> <p>2.2 Recovery</p> <p>Recovery is intended as "the ability to function in the community, socially and vocationally, as well as being relatively free of disease‐related psychopathology" (<a href="./references#CD015332-bbs2-0010" title="AndreasenN , CarpenterW , KaneJ , LasserR , MarderS , WeinbergerD . Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry2005;62:441-9. [PMID: 15741458]">Andreasen 2005</a>). We extracted the number of participants in recovery, based on this definition or on similar definitions provided in the studies. </p> <p>2.3 Remission</p> <p>Symptomatic remission according to Andreasen criteria (<a href="./references#CD015332-bbs2-0010" title="AndreasenN , CarpenterW , KaneJ , LasserR , MarderS , WeinbergerD . Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry2005;62:441-9. [PMID: 15741458]">Andreasen 2005</a>). </p> <p>2.4 Clinically important change in global state (e.g. global impression of much improved, or more than 50% improvement on a rating scale such as Clinical Global Impression (CGI)) </p> <p>2.5 Average endpoint or change score on a global state scale</p> </section> <section id="CD015332-sec-0034"> <h6 class="title">3. Service use</h6> <p>3.1 Admission to hospital</p> <p>3.2 Number of days in hospital</p> </section> <section id="CD015332-sec-0035"> <h6 class="title">4. Leaving the study early</h6> <p>4.1 For any reason</p> <p>4.2 Due to inefficacy</p> <p>4.3 Due to adverse effect</p> </section> <section id="CD015332-sec-0036"> <h6 class="title">5. Functioning</h6> <p>5.1 Clinically important change in functioning</p> <p>Number of participants with a clinically important change in functioning, as defined in each study. </p> <p>5.2 Average endpoint or change score on functioning scale</p> <p>We accepted any published rating scales such as the Global Assessment of Functioning (GAF) or the Psychosocial Performance Scale (PSP). </p> </section> <section id="CD015332-sec-0037"> <h6 class="title">6. Cognitive functioning</h6> <p>6.1 Clinically important change in cognitive functioning</p> <p>6.2 Average endpoint or change score on cognitive functioning scale</p> <p>We accepted any published cognitive functioning scale (e.g. the MATRICS consensus cognitive battery or the Neuropsychological Assessment Battery). </p> </section> <section id="CD015332-sec-0038"> <h6 class="title">7. Quality of life</h6> <p>7.1 Clinically important change in quality of life</p> <p>7.2 Average endpoint or change score on quality of life scale</p> <p>We accepted any published quality of life scale (e.g. Heinrich‐Carpenter Quality of Life Scale). </p> </section> <section id="CD015332-sec-0039"> <h6 class="title">8. Satisfaction with care</h6> <section id="CD015332-sec-0040"> <p><b>8.1 Recipient</b></p> <p>8.1.1 Recipient satisfied with care</p> <p>8.1.2 Average endpoint or change score on satisfaction with care scale</p> <p>We accepted any published rating scale measuring satisfaction with care.</p> </section> <section id="CD015332-sec-0041"> <p><b>8.2 Carers</b></p> <p>8.2.1 Carers satisfied with care</p> <p>8.2.2 Average endpoint or change score on satisfaction with care scale</p> </section> </section> <section id="CD015332-sec-0042"> <h6 class="title">9. Behaviour</h6> <p>9.1 Occurrence of violent incidents (to self, others, or property)</p> <p>9.2 Self‐injury</p> <p>9.3 Suicide attempt</p> </section> <section id="CD015332-sec-0043"> <h6 class="title">10. Adverse events/effects</h6> <p>10.1 At least one adverse event/effect</p> <p>10.2 Specific adverse events</p> <p>We used the classification proposed by Linden and colleagues to record adverse events potentially connected with CBT (<a href="./references#CD015332-bbs2-0053" title="LindenM , Schermuly­-Haupt M­L. Definition, assessment and rate of psychotherapy side effects. World Psychiatry2014;13:306-9.">Linden 2014</a>). </p> <p>10.3 Incidence of various specific adverse effects</p> <p>10.4 Average endpoint or change score on adverse effects scale</p> </section> <section id="CD015332-sec-0044"> <h6 class="title">11. Mortality</h6> <p>11.1 Overall mortality</p> <p>11.2 Mortality due to natural causes</p> <p>11.3 Mortality due to suicide</p> </section> <section id="CD015332-sec-0045"> <h6 class="title">12. Economic outcomes</h6> <p>12.1 Costs due to treatment</p> <p>12.2 Total direct and indirect costs</p> <p>12.3 Average change in total cost of medical and mental health care</p> </section> </section> </section> </section> <section id="CD015332-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015332-sec-0047"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched the register of the Cochrane Schizophrenia Group up to 6 March 2022 using the following search strategy: </p> <p>*Cognit* in Intervention Field of STUDY</p> <p>In such a study‐based register, searching the major concept retrieves all the synonyms and relevant studies. This is because the studies have already been organised, based on their interventions, and linked to the relevant topics (<a href="./references#CD015332-bbs2-0075" title="ShokranehF , AdamsCE . Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis. Bio Impacts2017;7(4):209-17. [DOI: 10.15171/bi.2017.25]">Shokraneh 2017</a>). This allows rapid and accurate searches that reduce waste in the next steps of systematic reviewing (<a href="./references#CD015332-bbs2-0076" title="ShokranehF , AdamsCE . Study-based registers reduce waste in systematic reviewing: discussion and case report. Systematic Reviews2019;8:129. [DOI: 10.1186/s13643-019-1035-3]">Shokraneh 2019</a>). </p> <p>Following Cochrane methods (<a href="./references#CD015332-bbs2-0047" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , MetzendorfM , et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Lefebvre 2021</a>), the Information Specialist compiles this register from systematic searches of major resources and their monthly updates (unless otherwise specified). </p> <p> <ul id="CD015332-list-0001"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library</p> </li> <li> <p>MEDLINE</p> </li> <li> <p>Embase</p> </li> <li> <p>Allied and Complementary Medicine Database (AMED)</p> </li> <li> <p>BIOSIS</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL)</p> </li> <li> <p>PsycINFO</p> </li> <li> <p>PubMed</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://www.who.int/clinical-trials-registry-platform" target="_blank">www.who.int/clinical-trials-registry-platform</a>) </p> </li> <li> <p>ProQuest Dissertations &amp; Theses A&amp;I and its quarterly update</p> </li> </ul> </p> <p>The register of the Cochrane Schizophrenia Group also includes handsearches and conference proceedings (see the Group's <a href="https://schizophrenia.cochrane.org/register-trials" target="_blank">website</a>). It does not place any limitations on language, date, document type, or publication status. </p> </section> <section id="CD015332-sec-0048"> <h4 class="title">Searching other resources</h4> <section id="CD015332-sec-0049"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of the included studies for further relevant studies.</p> </section> <section id="CD015332-sec-0050"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for any information regarding unpublished trials. We noted the outcome of this contact in the 'Characteristics of included studies' or 'Characteristics of studies awaiting classification' tables. </p> </section> </section> </section> <section id="CD015332-sec-0051"> <h3 class="title" id="CD015332-sec-0051">Data collection and analysis</h3> <section id="CD015332-sec-0052"> <h4 class="title">Selection of studies</h4> <p>At least two review authors (IB, OC and NHS) independently inspected citations from the searches and identified potentially relevant abstracts. Where disputes arose, we acquired the full report for more detailed scrutiny. We then obtained the full reports of the abstracts or reports deemed potentially relevant, and at least two review authors (IB, OC and NHS) independently inspected the full reports of the abstracts or reports for inclusion in the review. Where it was not possible to resolve a disagreement by discussion, we consulted the senior author of the team. If disagreement persisted, we attempted to contact the study authors for clarification. We documented all decisions made. </p> </section> <section id="CD015332-sec-0053"> <h4 class="title">Data extraction and management</h4> <section id="CD015332-sec-0054"> <h5 class="title">1. Extraction</h5> <p>At least two review authors (IB and OC) independently extracted data from the included studies. Where possible, we attempted to extract data presented only in graphs and figures, but included these data only if two review authors independently obtained the same result. Any disagreements were discussed. Where it was not possible to resolve disagreements by discussion, we consulted the senior review author. We documented all decisions. If necessary, we attempted to contact authors through an open‐ended request to obtain missing information or for clarification. Review author SL helped clarify issues regarding any remaining problems, and we documented these final decisions. </p> </section> <section id="CD015332-sec-0055"> <h5 class="title">2. Management</h5> <section id="CD015332-sec-0056"> <h6 class="title">2.1 Forms</h6> <p>We extracted data using pre‐designed forms developed specifically for this review.</p> </section> <section id="CD015332-sec-0057"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ul id="CD015332-list-0002"> <li> <p>the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD015332-bbs2-0054" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249-52.">Marshall 2000</a>); </p> </li> <li> <p>the measuring instrument has not been written or modified by one of the trialists for that particular trial; and </p> </li> <li> <p>the instrument should be a global assessment of an area of functioning and not subscores which are not in themselves validated or shown to be reliable. However, we will include subscores of scales if these were validated, or if these were predefined in a scale such as the positive symptom, negative symptom, and general symptom scores of the PANSS (<a href="./references#CD015332-bbs2-0041" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>). </p> </li> </ul> </p> <p>Ideally, the measurement instrument should either be a self‐report or be completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly. </p> </section> <section id="CD015332-sec-0058"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data: change data can remove a component of between‐person variability from the analysis; however, calculation of change needs two assessments (baseline and endpoint), which can be difficult to obtain in unstable and difficult‐to‐measure conditions such as schizophrenia. We have decided to primarily use endpoint data, and only use change data if the former were not available. If necessary, we combined endpoint and change data in the analysis. This procedure is possible when using mean differences (MDs) (<a href="./references#CD015332-bbs2-0021" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Deeks 2011</a>), and also when using standardised mean differences (SMDs). Although, theoretically, the combination of change and endpoint data when SMDs are used can be problematic, meta‐epidemiological research has shown that on average no major over‐ or underestimations can be expected (<a href="./references#CD015332-bbs2-0019" title="Da CostaBR , NüeschE , RutjesAW , JohnstonBC , ReichenbachS , TrelleS , et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. Journal of Clinical Epidemiology2013;66(8):847-55. [DOI: 10.1016/j.jclinepi.2013.03.009]">Da Costa 2013</a>). We planned to analyse endpoint and change data separately in a sensitivity analysis for the primary outcome mental state (<a href="#CD015332-sec-0094">Sensitivity analysis</a>). </p> </section> <section id="CD015332-sec-0059"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following checks to relevant continuous data before inclusion. </p> <p>For endpoint data from studies including fewer than 200 participants, we calculated the observed mean minus the lowest possible value of the scale and divided this by the standard deviation (<a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). </p> <p>For example, in a scale that has possible lowest values higher than 0 (such as the PANSS, which can have values from 30 to 210) (<a href="./references#CD015332-bbs2-0041" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>), we subtracted the minimum score (in this case 30) from the observed mean, and then divided by the standard deviation. In a scale that has 0 as the minimum possible score, we divided the observed mean by the standard deviation. </p> <p>For this calculation, we checked the original publication of the scales referenced in the studies to determine if they can have a lowest possible score different from 0, and whether the adjustment described above was needed. </p> <p>If the ratio obtained is lower than one, it strongly suggests that data are skewed. If it is higher than one but less than two, there is the suggestion that data are skewed; if the ratio is larger than two, we included these data, because it is less likely that they were skewed (<a href="./references#CD015332-bbs2-0008" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200.">Altman 1996</a>). </p> <p>Where there is the suggestion of skewedness (ratio &lt; 2), we excluded the relevant studies in a sensitivity analysis to determine if they have an impact on the results (see <a href="#CD015332-sec-0094">Sensitivity analysis</a>). </p> <p>These skewed results would nevertheless be reported in 'Additional tables'.</p> <p>We planned to enter all relevant data from studies of more than 200 participants in the analysis irrespective of the above rules, because skewed data pose less of a problem in large studies. We also planned to enter all relevant change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether or not data are skewed. </p> </section> <section id="CD015332-sec-0060"> <h6 class="title">2.5 Common measurement</h6> <p>To facilitate comparison between trials, we aimed, where relevant, to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week, or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD015332-sec-0061"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we attempted to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that, if there is a 50% reduction in a scale‐derived score such as the BPRS, <a href="./references#CD015332-bbs2-0068" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799-812.">Overall 1962</a>, or the PANSS, <a href="./references#CD015332-bbs2-0041" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>, which corresponds to 'much improved' according to the CGI, <a href="./references#CD015332-bbs2-0031" title="GuyW . Clinical Global Impression scale (CGI). ECDEU assessment manual for psychopharmacology. Rev. Rockville, MD: US National Institutes of Health. Psychopharmacology Research Branch, 1976.">Guy 1976</a>, of raters, this could be considered a clinically significant response (<a href="./references#CD015332-bbs2-0050" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366-71. [PMID: 16199797]">Leucht 2005a</a>; <a href="./references#CD015332-bbs2-0051" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?Schizophrenia Research2005;79(2-3):231-8. [PMID: 15982856]">Leucht 2005b</a>), in particular for acutely ill participants. If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors, because the exact cut‐off is not so important in a meta‐analysis using risk ratios or odds ratios as effect sizes (<a href="./references#CD015332-bbs2-0027" title="FurukawaTA , AkechiT , WagenpfeilS , LeuchtS . Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research2011;126:212-9. [DOI: 10.1016/j.schres.2010.10.016]">Furukawa 2010</a>). </p> </section> <section id="CD015332-sec-0062"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data such that the area to the left of the line of no effect indicated a favourable outcome for CBT. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'not un‐improved'), we reported data where the left of the line indicated an unfavourable outcome and noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD015332-sec-0063"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (OC and IB) independently assessed risk of bias using the Cochrane RoB 2 tool, referring to the criteria described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>; <a href="./references#CD015332-bbs2-0077" title="SterneJAC , SavovićJ , PageMJ , ElbersRGE , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:I4898.">Sterne 2019</a>). </p> <p>The risk of bias assessment is based on the following criteria:</p> <p> <ul id="CD015332-list-0003"> <li> <p>bias arising from the randomisation process;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome; and</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>For each domain, we rated the available 'signalling questions' to reach a judgement of low risk of bias, some concerns, or high risk of bias, following the tool algorithms implemented in the RoB 2 Excel tool (available at <a href="https://www.riskofbias.info/" target="_blank">www.riskofbias.info</a>). </p> <p>RoB 2 generally allows assessors to address studies from two angles: 1) effect of assignment to the interventions at baseline, regardless of whether the interventions were received as intended ('intention‐to‐treat effect'); 2) adherence to the interventions ('per‐protocol effect') (Chapter 8.2.2, <a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). For the purposes of this review, we aimed to assess the intention‐to‐treat effect. </p> <p>We performed an evaluation with the RoB 2 tool for the following outcomes.</p> <p> <ul id="CD015332-list-0004"> <li> <p>Mental state: average endpoint or change score on a general mental state scale (e.g. PANSS, BPRS) (primary outcome) – medium term </p> </li> <li> <p>Global state: relapse – long term</p> </li> <li> <p>Leaving the study early: leaving the study early for any reason – medium term</p> </li> <li> <p>Functioning: average endpoint or change score on functioning scale – medium term</p> </li> <li> <p>At least one adverse event – long term</p> </li> </ul> </p> <p>For cluster‐randomised trials, we planned to use RoB 2 for cluster‐randomised trials, provided at <a href="https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool" target="_blank">sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool</a>. </p> <p>For cross‐over trials, as we intended to only use data from the first phase (see <a href="#CD015332-sec-0064">Measures of treatment effect</a>), we planned to use the standard version of RoB 2. </p> <p>In the case of disagreement, we made the final rating by consensus. Where inadequate details of randomisation and other characteristics of trials were provided, we attempted to contact the study authors to obtain further information. We reported non‐concurrence in quality assessment, but if disputes arose regarding the category to which a trial was to be allocated, we resolved this by discussion. </p> <p>We noted the level of risk of bias in both the text of the review, the relevant forest plots, and the summary of findings table/s. </p> </section> <section id="CD015332-sec-0064"> <h4 class="title">Measures of treatment effect</h4> <section id="CD015332-sec-0065"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI), as it has been shown that RR is more intuitive than odds ratios (<a href="./references#CD015332-bbs2-0017" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405-11. [PMID: 10667106]">Boissel 1999</a>), and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD015332-bbs2-0020" title="DeeksJ . Issues in the selection for meta-analyses of binary data. In: 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.">Deeks 2000</a>). Although the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH), with their CIs, are intuitively attractive to clinicians, they are problematic to calculate and interpret in meta‐analyses (<a href="./references#CD015332-bbs2-0037" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27-30. [PMID: 19438480]">Hutton 2009</a>). For binary data presented in the summary of findings table/s, we calculated illustrative comparative risks where possible. </p> </section> <section id="CD015332-sec-0066"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated MD between groups, in particular when natural measures (such as days, kilograms, etc.) were used. We prefer not to calculate standardised effect size measures (SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated SMD. It should be noted that SMD can be transformed to MD by using the formula MD = SMD x standard deviation of the scale of interest (<a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). </p> </section> </section> <section id="CD015332-sec-0067"> <h4 class="title">Unit of analysis issues</h4> <section id="CD015332-sec-0068"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but the analysis and pooling of clustered data pose problems. Authors often fail to account for intraclass correlation in clustered studies, leading to a unit of analysis error whereby P values are spuriously low, CIs unduly narrow, and statistical significance overestimated (<a href="./references#CD015332-bbs2-0022" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623-9.">Divine 1992</a>). This causes type I errors (<a href="./references#CD015332-bbs2-0016" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315(7108):600.">Bland 1997</a>; <a href="./references#CD015332-bbs2-0030" title="GullifordMC . Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876-83.">Gulliford 1999</a>). </p> <p>We planned that where clustering was incorporated into the analysis of primary studies, we would present these data as if from a non‐cluster randomised study, but adjust for the clustering effect. </p> <p>Where clustering was not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. We planned to attempt to contact the first authors of studies to obtain intraclass correlation coefficients (ICCs) for their clustered data and to adjust for this using accepted methods (<a href="./references#CD015332-bbs2-0030" title="GullifordMC . Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876-83.">Gulliford 1999</a>). </p> <p>We have sought statistical advice and have been advised that the binary data from cluster trials presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC: thus design effect = 1 + (m − 1) * ICC (<a href="./references#CD015332-bbs2-0023" title="DonnerA , KlarN . Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine2002;21(19):2971-80.">Donner 2002</a>). If the ICC was not reported, we would assume it to be 0.1 (<a href="./references#CD015332-bbs2-0079" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii-92.">Ukoumunne 1999</a>). </p> <p>If cluster studies were appropriately analysed and had taken ICCs and relevant data documented in the report into account, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD015332-sec-0069"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. This occurs if an effect (e.g. pharmacological, physiological, or psychological) of the treatment in the first phase is carried over to the second phase. As a result, participants can differ significantly from their initial state at entry to the second phase, despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD015332-bbs2-0025" title="ElbourneD , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). As both carry‐over and unstable conditions are very likely in severe mental illness, we planned to only use data from the first phase of cross‐over studies. </p> </section> <section id="CD015332-sec-0070"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two relevant treatment arms, we presented each different treatment arm in the relevant comparison. </p> </section> </section> <section id="CD015332-sec-0071"> <h4 class="title">Dealing with missing data</h4> <section id="CD015332-sec-0072"> <h5 class="title">1. Overall loss of credibility</h5> <p>Although at some degree of loss of follow‐up data lose credibility (<a href="./references#CD015332-bbs2-0081" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El-SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254-7.">Xia 2009</a>), we did not exclude studies based on this. </p> <p>However, if more than 50% of data were unaccounted for (lost to follow‐up), we would exclude these studies in a sensitivity analysis (<a href="#CD015332-sec-0094">Sensitivity analysis</a>). If more than 50% of data in one arm of a study were lost, but the total loss was less than 50%, we would address this in the summary of findings table/s by downgrading the certainty of the evidence (and not exclude the study in the sensitivity analysis). Finally, we also downgraded the certainty of the evidence in the summary of findings table/s if the loss was 25% to 50% in total. </p> </section> <section id="CD015332-sec-0073"> <h5 class="title">2. Binary</h5> <p>We presented data using an intention‐to‐treat (ITT) analysis. If studies presented data only on completers, we still used these studies and planned to undertake a sensitivity analysis excluding studies using completer analyses (<a href="#CD015332-sec-0094">Sensitivity analysis</a>). </p> </section> <section id="CD015332-sec-0074"> <h5 class="title">3. Continuous</h5> <section id="CD015332-sec-0075"> <h6 class="title">3.1 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we would attempt to obtain the missing values from the study authors. If these were not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and CIs were available for group means, and either P value or t value available for differences in the mean, we would calculate SDs according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). When only the SE is reported, SDs are calculated by the formula SD = SE * √(n). The <i>Cochrane Handbook</i> presents detailed formulae for estimating SDs from P, t or F values, CIs, ranges, or other statistics (<a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). If these formulae did not apply, we would calculate the SDs according to a validated imputation method that is based on the SDs of the other included studies (<a href="./references#CD015332-bbs2-0026" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7-10.">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. Nevertheless, we would have examined the validity of the imputations in a sensitivity analysis that excludes imputed values. </p> </section> <section id="CD015332-sec-0076"> <h6 class="title">3.2 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or who were lost to follow‐up. Some trials simply present the results of study completers; others use the method of last‐observation‐carried‐forward (LOCF). More recently, methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD015332-bbs2-0048" title="LeonAC , MallinckrodtCH , Chuang-SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001-5. [PMID: 16905632]">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences between groups in their reasons for doing so is often the core problem in randomised schizophrenia trials, therefore we did not exclude studies based on the statistical approach used. However, by preference, we used the more sophisticated approaches, that is we preferred to use MMRM or multiple‐imputation to LOCF, and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the 'missing outcome data' item of the RoB 2 tool. </p> </section> </section> </section> <section id="CD015332-sec-0077"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD015332-sec-0078"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for participants who were clearly outliers or situations that arose that had not been predicted, and, where found, discussed with other review authors such situations or participant groups. </p> </section> <section id="CD015332-sec-0079"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods that we had not predicted would arise and discussed with other review authors any such methodological outliers. </p> </section> <section id="CD015332-sec-0080"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD015332-sec-0081"> <h6 class="title">3.1 Visual inspection</h6> <p>We inspected graphs visually to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD015332-sec-0082"> <h6 class="title">3.2 Using the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² statistic alongside the Chi² P value. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD015332-bbs2-0033" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). The importance of the observed value of I² depends on the magnitude and direction of effects as well as the strength of evidence for heterogeneity (e.g. P value from Chi² test, or a CI for I²). We interpreted the I² statistic as follows (Chapter 10, <a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>): </p> <p> <ul id="CD015332-list-0005"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>We planned that if we found substantial levels of heterogeneity in the primary outcome, we would explore reasons for the heterogeneity (<a href="#CD015332-sec-0087">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD015332-sec-0083"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD015332-bbs2-0024" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). These are described in Chapter 13 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). </p> <section id="CD015332-sec-0084"> <h5 class="title">1. Protocol versus full study</h5> <p>We attempted to locate protocols of the included trials. If the protocol was available, we compared the outcomes in the protocol with those in the published report. If the protocol was not available, we compared the outcomes listed in the methods section of the trial report with the reported results. If details from ClinicalTrials.gov and WHO ICTRP were available, they would have been included in the search results, and could be used to compare the differences between planned methods and published results. </p> </section> <section id="CD015332-sec-0085"> <h5 class="title">2. Funnel plot</h5> <p>We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were fewer than 10 studies, or where all studies were of similar size. Where funnel plots were possible, we planned to seek statistical advice on their interpretation. We planned to additionally apply the Egger's test for funnel plot asymmetry to support the visual inspection of the forest plot with a statistical test. We planned to perform Egger's test with <a href="./references#CD015332-bbs2-0069" title="R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2017. Available at www.R-project.org.">R</a>. </p> </section> </section> <section id="CD015332-sec-0086"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument regarding preference for the use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us, and the random‐effects model takes into account differences between studies, even if there is no statistically significant heterogeneity. However, there is a disadvantage to the random‐effects model in that it puts added weight onto small studies, which are often the most biased studies. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose to use a random‐effects model for analyses. We planned to apply the fixed‐effect model in a sensitivity analysis of the primary outcome. </p> </section> <section id="CD015332-sec-0087"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD015332-sec-0088"> <h5 class="title">1. Subgroup analyses</h5> <p>We planned to conduct the following subgroup analysis for the primary outcome if at least 10 studies were included in the analysis (<a href="./references#CD015332-bbs2-0034" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020) Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). Since no analyses included at least 10 studies, it was not possible to conduct any subgroup analyses. </p> <section id="CD015332-sec-0089"> <h6 class="title">1.1 Stage of the illness</h6> <p>We planned to separately investigate studies that enrolled chronic participants and studies that enrolled participants at their first episode of psychosis. </p> </section> <section id="CD015332-sec-0090"> <h6 class="title">1.2 Special populations</h6> <p>We planned to investigate the effect of the intervention in different subpopulations if data were provided separately (e.g. participants with schizophrenia versus participants with other psychotic disorders such as schizophreniform disorder, schizoaffective disorder, and delusional disorder). </p> </section> <section id="CD015332-sec-0091"> <h6 class="title">1.3 Individual versus group</h6> <p>We planned to separately investigate studies that provided CBT in an individual versus in a group setting. </p> </section> <section id="CD015332-sec-0092"> <h6 class="title">1.4 Clinical staff training</h6> <p>We planned to separately investigate studies in which CBT was delivered by different professionals (e.g. therapists expert in CBT, therapists in training, nurses). </p> </section> </section> <section id="CD015332-sec-0093"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We reported if inconsistency was substantial. Firstly, we investigated whether data had been entered correctly. If they had, we would consider the following strategies: </p> <p> <ul id="CD015332-list-0006"> <li> <p>pool data despite the heterogeneity. An example where this strategy may be appropriate is when the effects of all studies are in the same direction. In other words, the heterogeneity reflects the degree of an effect rather than its direction, which is less problematic. Another example is when heterogeneity can be explained by appropriate subgroup analyses; </p> </li> <li> <p>exclude outlying studies. This strategy may apply if re‐inspection of such studies revealed methodological or clinical differences that were previously overlooked; </p> </li> <li> <p>not pool the studies.</p> </li> </ul> </p> <p>All decisions in this regard have been described and discussed.</p> </section> </section> <section id="CD015332-sec-0094"> <h4 class="title">Sensitivity analysis</h4> <p>Where possible, we planned to perform sensitivity analyses for the primary outcome to explore the influence of the factors listed below on effect size. We planned that where there were substantial differences in the direction or precision of effect estimates in any of these sensitivity analyses, we would discuss them in the <a href="#CD015332-sec-0217">Discussion</a>. However, since no comparison included more than three studies, we did not perform any sensitivity analyses. </p> <section id="CD015332-sec-0095"> <h5 class="title">1. Blinding of outcome assessor</h5> <p>We planned to exclude studies that did not apply a blind outcome assessor.</p> </section> <section id="CD015332-sec-0096"> <h5 class="title">2. Assumptions for missing data</h5> <p>We planned to exclude studies using completer analyses only (see <a href="#CD015332-sec-0071">Dealing with missing data</a>). </p> </section> <section id="CD015332-sec-0097"> <h5 class="title">3. Loss to follow‐up</h5> <p>We planned to exclude studies where the overall loss of data was greater than 50%.</p> </section> <section id="CD015332-sec-0098"> <h5 class="title">4. Risk of bias</h5> <p>We planned to analyse the effects of excluding trials at overall high risk of bias (see <a href="#CD015332-sec-0063">Assessment of risk of bias in included studies</a>). </p> </section> <section id="CD015332-sec-0099"> <h5 class="title">5. Imputed values</h5> <p>We planned to undertake a sensitivity analysis excluding trials where imputed values were used for ICC in calculating the design effect in cluster‐randomised trials or where SDs were imputed. </p> </section> <section id="CD015332-sec-0100"> <h5 class="title">6. Fixed‐effect</h5> <p>We synthesised data using the random‐effects model; however, we also planned to synthesise data for the primary outcome using a fixed‐effect model to evaluate whether this altered the significance of the results. </p> </section> <section id="CD015332-sec-0101"> <h5 class="title">7. Separating endpoint and change data</h5> <p>We planned to analyse studies providing data in the form of endpoint scores and change scores separately for the continuous primary outcome mental state. </p> </section> <section id="CD015332-sec-0102"> <h5 class="title">8. Skewed data</h5> <p>We planned to perform a sensitivity analysis excluding studies for which there was the suggestion of skewedness (mean/SD ratio lower than 2; see <a href="#CD015332-sec-0053">Data extraction and management</a>). We planned that if this changed the results in comparison with the main analysis (from significantly favouring the intervention to significantly favouring the control, or vice versa), we would exclude these studies from the main analysis and present their data in 'Additional tables'. </p> </section> </section> <section id="CD015332-sec-0103"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD015332-sec-0104"> <h5 class="title">Summary of findings table</h5> <p>We used the GRADE approach to interpret findings (<a href="./references#CD015332-bbs2-0073" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al, Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>), and employed GRADEpro GDT software to export data from the review to create summary of findings tables (<a href="./references#CD015332-bbs2-0029" title="GRADEpro GDT. Version accessed 6 August 2016. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD015332-bbs2-0070" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). These tables provide outcome‐specific information concerning the overall certainty of evidence from each study included in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rate as important to patient care and decision‐making. The overall RoB 2 judgements were used to feed into the GRADE assessment. We selected the following main outcomes for inclusion in the summary of findings tables. </p> <p> <ul id="CD015332-list-0007"> <li> <p>Mental state: average endpoint or change score on a general mental state scale (e.g. PANSS, BPRS) (primary outcome) – medium term </p> </li> <li> <p>Global state: relapse – long term</p> </li> <li> <p>Leaving the study early: leaving the study early for any reason – medium term</p> </li> <li> <p>Functioning: average endpoint or change score on functioning scale – medium term</p> </li> <li> <p>At least one adverse event – long term</p> </li> </ul> </p> <p>If data were not available for these prespecified outcomes but were available for similar ones, we presented the closest outcome to the prespecified one in the summary of findings table, but took this into account when grading the finding. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015332-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015332-sec-0105"></div> <section id="CD015332-sec-0106"> <h3 class="title">Description of studies</h3> <p>For details, see <a href="#CD015332-sec-0108">Included studies</a> and <a href="#CD015332-sec-0117">Excluded studies</a>. </p> <section id="CD015332-sec-0107"> <h4 class="title">Results of the search</h4> <p>Our search of the Cochrane Schizophrenia Group's Study‐Based Register of Trials identified 1387 eligible records; 1 additional record was retrieved by handsearching. We excluded 1349 records based on title and abstract. We assessed the remaining 38 full‐text articles and included 4 studies (29 full‐text articles) (<a href="#CD015332-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD015332-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD015332-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD015332-sec-0108"> <h4 class="title">Included studies</h4> <p>We included 4 studies (300 participants); all trials contributed to the meta‐analysis.</p> <section id="CD015332-sec-0109"> <h5 class="title">1. Design and duration</h5> <p>All studies were RCTs. The studies had an intervention period of 26 to 39 weeks and a follow‐up period of 26 to 104 weeks (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>; <a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>; <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). One study was triple‐blind (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>); the other three studies employed a blind rater. </p> </section> <section id="CD015332-sec-0110"> <h5 class="title">2. Participants</h5> <p>Participants in one study were diagnosed using <i>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</i> (<i>DSM‐IV</i>) criteria (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>); the remaining three studies used the International Classification of Diseases 10th Revision (ICD‐10) (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>; <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). Two studies also accepted participants who met entry criteria for an early intervention for psychosis service (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>; <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>), while the other two studies specifically recruited first episode patients, also including children and adolescents (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). The average age of participants was 21.94 years. </p> </section> <section id="CD015332-sec-0111"> <h5 class="title">3. Size</h5> <p>The mean number of participants was 75. The smallest study included 61 participants (<a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>), and the largest study included 90 participants (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>). </p> </section> <section id="CD015332-sec-0112"> <h5 class="title">4. Setting</h5> <p>Participants were recruited in oupatient service in two studies (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>; <a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>), and both inpatient‐outpatient settings in one study (<a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>); this information was unclear in the remaining study (<a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). Three studies were conducted in the UK (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>; <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>), and one study was conducted in Australia (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>). </p> </section> <section id="CD015332-sec-0113"> <h5 class="title">5. Interventions</h5> <p>All studies had an intervention group using CBT techniques, and the intervention was manualised. Two studies planned 26 CBT sessions (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>; <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>); one study planned 24 CBT sessions (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>); and this information was not specified in the remaining study (<a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). Therapy was provided face‐to‐face and individually in all studies. Pharmacotherapy was allowed in all studies. </p> </section> <section id="CD015332-sec-0114"> <h5 class="title">6. Outcomes</h5> <p>Scales used to assess symptoms and other conditions varied. Study reporting was in some cases incomplete, and authors were approached for missing outcome data and clarifications by email. The supplementary materials and appendices were also inspected and used as a source of data. </p> <section id="CD015332-sec-0115"> <h6 class="title">6.1. Outcome scales</h6> <p>6.1.1 Mental state</p> <p>Brief Psychiatric Rating Scale (BPRS) (<a href="./references#CD015332-bbs2-0068" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799-812.">Overall 1962</a>) </p> <p>BPRS is a clinician‐rated scale used to quantify the severity of psychiatric symptoms, including psychotic symptoms. The most commonly used form of the scale has 18 items that include positive, negative, and affective symptoms. Each item is graded on a 7‐point Likert scale ranging from 1 to 7 (1 "not present" and 7 "very severe"). A total score can be obtained by summing the scores of all items as a measure of overall schizophrenia symptoms (range from 18 to 126, a higher number showing higher severity of symptoms). One study used the BPRS (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>). </p> <p>Positive and Negative Syndrome Scale (PANSS) (<a href="./references#CD015332-bbs2-0041" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>) </p> <p>Created using the BPRS (see above), the PANSS is a 30‐item clinician‐rated assessment that includes positive, negative, and general psychopathology symptoms of schizophrenia. Each item is graded on a 7‐point Likert scale (1 "absent" and 7 "severe"). A total score can be derived by adding the scores of all items as a measure of overall schizophrenia symptoms (ranging from 30 to 210, a higher score showing higher severity of the condition). PANSS comprises three subscales: 1) positive syndromes, 2) negative syndromes, and 3) general psychopathology. Three studies used the PANSS (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>; <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). </p> <p>Scale for the Assessment of Negative Symptoms (SANS) (<a href="./references#CD015332-bbs2-0009" title="AndreasenNC . The scale for the assessment of negative symptoms (SANS). Rinsho Seishin Igaku1984;13:999-1010. [https://cir.nii.ac.jp/crid/1573105975030325632]">Andreasen 1984</a>) </p> <p>The first instrument developed to provide a comprehensive assessment of negative symptoms in schizophrenia was the Scale for the Assessment of Negative Symptoms (SANS) (<a href="./references#CD015332-bbs2-0009" title="AndreasenNC . The scale for the assessment of negative symptoms (SANS). Rinsho Seishin Igaku1984;13:999-1010. [https://cir.nii.ac.jp/crid/1573105975030325632]">Andreasen 1984</a>), which consists of five scales that assess five different aspects of negative symptoms: affective blunting, alogia, avolition‐apathy, anhedonia‐asociality, and attentional impairment. Each of these negative symptoms can be rated globally, but in addition detailed observations are made to achieve the global rating. </p> <p>Scale for the Assessment of Positive Symptoms (SAPS)</p> <p>The SAPS permits a detailed evaluation and global ratings of hallucinations, delusions, positive formal thought disorder, and bizarre behaviour (<a href="./references#CD015332-bbs2-0009" title="AndreasenNC . The scale for the assessment of negative symptoms (SANS). Rinsho Seishin Igaku1984;13:999-1010. [https://cir.nii.ac.jp/crid/1573105975030325632]">Andreasen 1984</a>). </p> <p>Hospital Anxiety and Depression Scale (HADS) (<a href="./references#CD015332-bbs2-0082" title="ZigmondAS , SnaithRP . The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica1983;67(6):361-370. [DOI: 10.1111/j.1600-0447.1983.tb09716.x]">Zigmond 1983</a>) </p> <p>HADS was developed by Zigmond and Snaith in 1983 and is a self‐assessment scale used for screening purposes to determine anxiety and depression, not for diagnosis. The 14‐item HADS includes the anxiety subscale (HADS‐A) and the depression subscale (HADS‐D), each consisting of 7 items. A score between 0 and 3 is obtained for each item by choosing from among four options. By adding the subscale scores, a total of 0 to 21 points can be obtained from each of the depression and anxiety subscales. Zero to 7 points for each subscale are in the normal range; 8 to 10 points suggest the presence of a mood disorder; and a score of 11 and above indicates possible mood disorder. Two studies used the HADS (<a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). </p> <p>Beck Depression Inventory (BDI) (<a href="./references#CD015332-bbs2-0012" title="BeckAT , WardCH , MendelsonM , MockJ , ErbaughJ . An inventory for measuring depression. Archives of General Psychiatry1961;4:561-71. [DOI: 10.1001/archpsyc.1961.01710120031004]">Beck 1961</a>) </p> <p>BDI is a 21‐item self‐reporting questionnaire for evaluating the severity of depression in normal and psychiatric populations. Developed by Beck and colleagues in 1961, it relied on the theory of negative cognitive distortions as central to depression. A total score is obtained by scoring each item between 0 and 3 points. Each of the 21 questions presents four different statements and asks respondents to select the option that best represents them. Statements refer to depressive states in varying degrees of severity (from “I do not feel sad” to “I am so sad or unhappy that I can’t stand it”). Only one study used the BDI (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>). </p> <p>Social Interaction Anxiety Scale (SIAS)</p> <p>The Social Interaction Anxiety Scale (SIAS) and its companion scale, the Social Phobia Scale (SPS), were created in response to a need for tools that assess various commonly feared social situations (<a href="./references#CD015332-bbs2-0056" title="MattickRP , ClarkeJC . Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behaviour Research and Therapy1998;36(4):455-470. [https://www.sciencedirect.com/science/article/abs/pii/S0005796797100316]">Mattick 1998</a>). The SIAS was developed on the premise that social anxiety manifests itself in two types of situations: those involving social interaction with others (e.g. initiating and maintaining conversation) and those involving being observed or scrutinised by others (e.g. giving a speech or eating in public) (<a href="./references#CD015332-bbs2-0056" title="MattickRP , ClarkeJC . Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behaviour Research and Therapy1998;36(4):455-470. [https://www.sciencedirect.com/science/article/abs/pii/S0005796797100316]">Mattick 1998</a>). The SIAS is an attempt to quantify the first of the two concepts, social interaction anxiety, and includes 20 questions rated on a 5‐point Likert scale ranging from "not at all typical of me" to "extremely typical of me". Items are self‐statements that describe how people react to interpersonal contacts in dyads or groups. Summing the ratings after opposite scoring three positively worded items yields a total SIAS score. Only one study used the SIAS (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>). </p> <p>6.1.2 Global state</p> <p>Clinical Global Impression (CGI) (<a href="./references#CD015332-bbs2-0031" title="GuyW . Clinical Global Impression scale (CGI). ECDEU assessment manual for psychopharmacology. Rev. Rockville, MD: US National Institutes of Health. Psychopharmacology Research Branch, 1976.">Guy 1976</a>) </p> <p>CGI is a clinically graded 7‐step scale consisting of two scales that measure overall disease severity (CGI‐Severity, or CGI‐S) and overall clinical improvement (CGI‐Improvement, or CGI‐I). Lower scores represent greater improvement in the disease (or less deterioration). A CGI‐I score of 1 "very much improved" or 2 "much improved" corresponds to a clinically meaningful improvement. One study used the CGI (<a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>). </p> <p>6.1.3 Functioning</p> <p>Personal and Social Performance Scale (PSP) (<a href="./references#CD015332-bbs2-0059" title="MorosiniPL , MaglianoL , BrambillaLA , UgoliniS , PioliR . Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica2000;101(4):323-329. [DOI: 10.1034/j.1600-0447.2000.101004323.x]">Morosini 2000</a>) </p> <p>PSP is a short scale with a 100‐point single‐item, with scores of 1 to 10 reflecting a lack of basic functional autonomy, and scores of 91 to 100 reflecting excellent functioning. Ratings are based on the evaluation of four objective indicators: "(a) socially useful activities, including work and study; (b) personal and social relationships, (c) self‐care, (d) disruptive and aggressive behavior". These are rated on a 6‐point severity scale (absent to extremely severe), following specific operational definitions (<a href="./references#CD015332-bbs2-0059" title="MorosiniPL , MaglianoL , BrambillaLA , UgoliniS , PioliR . Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica2000;101(4):323-329. [DOI: 10.1034/j.1600-0447.2000.101004323.x]">Morosini 2000</a>). Two studies used the PSP (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>; <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>). </p> <p>Social and Occupational Functioning Assessment Scale (SOFAS) (<a href="./references#CD015332-bbs2-0011" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: American Psychiatric Association, 1994.">APA 1994</a>) </p> <p>SOFAS was developed to assess the level of social and occupational functioning of individuals not directly affected by the overall severity of their psychiatric symptoms. The scale also takes into account the impact on a person's general health when assessing social and professional functioning. This scale, found in <i>DSM‐IV</i>, is used in particular to determine 5th axis features and to measure functionality. It ranges from 0 to 100 points, with higher scores indicating good functioning. One study used the SOFAS (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>). </p> <p>First Episode Social Functioning Scale (FESFS) (<a href="./references#CD015332-bbs2-0046" title="LecomteT , CorbièreM , EhmannT , AddingtonJ , Abdel-BakiA , MacEwanB . Development and preliminary validation of the First Episode Social Functioning Scale for early psychosis. Psychiatry Research2014;216(3):412-17. [DOI: 10.1016/j.psychres.2014.01.044]">Lecomte 2014</a>) </p> <p>FESFS was developed in 2014 by Lecomte and colleagues and assesses nine functional areas: "Life skills", "Interaction with people", "Friends and activities", "Intimacy", "Family", "Work relationships and social activities", "Work skills", "Interpersonal relationships and social activities at school” and “Educational skills”. The participant is asked to rate his or her perceived competencies and frequency of involvement in these areas on a scale from 1 to 4 (e.g. "strongly agree" to "strongly disagree" or "strongly disagree" to "always agree"). Higher scores indicate better social and occupational functioning. One study used the FESFS (<a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). </p> <p>6.1.4 Cognitive functioning</p> <p>No studies used a scale measuring cognitive functioning.</p> <p>6.1.5 Quality of life</p> <p>World Health Organization Quality of Life abbreviated form (WHOQOL‐BREF) (<a href="./references#CD015332-bbs2-0067" title="O'CarrollRE , SmithK , CoustonM , CossarJA , HayesPC . A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Quality of Life Research2000;9(1):121-24. [DOI: 10.1023/A:1008901320492]">O'Carroll 2000</a>) </p> <p>WHOQOL‐BREF is a self‐reported scale used to assess quality of life. It contains 26 questions about recent health satisfaction, psychological functioning, social relationships, and environmental opportunities. Each question is rated from 1 to 5 on a 5‐point Likert scale. An overall score of 26 to 130 is determined by summing the scores of all items, with higher scores indicating better quality of life. One study used the WHOQOL‐BREF (<a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>). </p> <p>EQ‐5D‐5L (<a href="./references#CD015332-bbs2-0078" title="EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy1990;16(3):199-208.">The EuroQol Group 1990</a>) </p> <p>EQ‐5D‐5L is a self‐report scale that measures quality of life. The five dimensions of the descriptive system are mobility, self‐care, usual activities, pain/discomfort, and anxiety/depression. There are five levels for each dimension: no problems, minor problems, moderate problems, severe problems, and extreme problems. The participant is asked to rate his or her health by checking the box beside the most suitable statement within each of the five dimensions. This decision yields a 1‐digit number expressing the level chosen for that dimension. The numbers for the five dimensions can be combined to generate a 5‐digit number that defines the person's health status. One study used the EQ‐5D‐5L (<a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). </p> <p>Quality of Life Scale (QLS) (<a href="./references#CD015332-bbs2-0032" title="HeinrichsDW , HanlonTE , Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin1984;10(3):388-398. [DOI: 10.1093/schbul/10.3.388]">Heinrichs 1984</a>) </p> <p>QLS is a 21‐item scale based on a semi‐structured interview designed to assess deficit symptoms in schizophrenia. It is made up of 21 items divided into 4 categories: 1) interpersonal relations, 2) instrumental role, 3) intrapsychic foundations, and 4) common objects and activities. Each item is rated on a 7‐point Likert scale ranging from 0 to 6, with a higher score representing less impairment in the past four weeks. One study used the QLS (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>). </p> </section> </section> <section id="CD015332-sec-0116"> <h5 class="title">7. Funding sources</h5> <p>All studies reported receiving public funding.</p> </section> </section> <section id="CD015332-sec-0117"> <h4 class="title">Excluded studies</h4> <p>We excluded three studies based on full‐text assessment. Reasons for exclusion were non‐randomised study design (<a href="./references#CD015332-bbs2-0005" title="MorrisonAP , HuttonP , WardleM , SpencerH , BarrattS , BrabbanA , et al. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychological Medicine2012;42(5):1049-56. [DOI: 10.1017/S0033291711001899]">Morrison 2012</a>), and lack of a CBT without antipsychotic arm (<a href="./references#CD015332-bbs2-0006" title="MorrisonA . A pilot randomised controlled trial of cognitive therapy for internalised stigma in people experiencing psychosis. Early Intervention In Psychiatry2016;10(S1):94. [DOI: 10.1111/eip.12396]MorrisonAP , BurkeE , MurphyE , PyleM , BoweS , VareseF , et al. Cognitive therapy for internalised stigma in people experiencing psychosis: A pilot randomised controlled trial. Psychiatry Research2016;240:96-102. [DOI: 10.1016/j.psychres.2016.04.024]">Morrison 2016</a>; <a href="./references#CD015332-bbs2-0007" title="ISRCTN99672552. Focusing on clozapine unresponsive symptoms trial. www.isrctn.com/ISRCTN99672552 (first received 28 November 2012). [DOI: 10.1186/ISRCTN99672552]MorrisonA . Cognitive behaviour therapy for people with psychosis. Schizophrenia Bulletin2019;45(S2):89. [DOI: 10.1093/schbul/sbz022.001]MorrisonAP , PyleM , GumleyA , SchwannauerM , TurkingtonD , MacLennanG , et al. Cognitive-behavioural therapy for clozapine-resistant schizophrenia: The FOCUS RCT. Health Technology Assessment2019;23(7):1-143. [DOI: 10.3310/hta23070]Morrison AP , PyleM , GumleyA , SchwannauerM , TurkingtonD , MacLennanG , et al. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. The Lancet Psychiatry2018;5(8):633-643. [DOI: 10.1016/ S2215-0366(18)30184-6]PyleM , NorrieJ , SchwannauerM , KingdonD , GumleyA , TurkingtonD , et al. Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. BMC Psychiatry2016;16(1):1-12. [DOI: 10.1186/s12888-016-0983-6]SchoolerN . Cognitive behavioural therapy for clozapine non-responders. The Lancet Psychiatry2018;5(8):607-608. [DOI: 10.1016/ S2215-0366(18)30256-6]">Morrison 2018 – FOCUS</a>). </p> <p>We identified no ongoing studies or studies awaiting classification.</p> </section> </section> <section id="CD015332-sec-0118"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessment for each of the predefined outcomes is located in the <a href="./references#CD015332-sec-0239" title="">Risk of bias (tables)</a>, including all domain judgements and support for judgements, and at the side of the relevant forest plots. Detailed risk of bias assessments are available upon request. </p> <p>Regarding overall risk of bias, one study had a low risk of bias (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>); one study had some concerns (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>); and two studies had a high risk of bias (<a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>). </p> <p>The main problem in the included studies was represented by domain deviations from intended interventions. The included studies tried to administer CBT without antipsychotics medication to at least one group of participants, which can be challenging. Indeed, during the trial there were deviations from the randomised intervention. </p> <p>In <a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>, some participants started to receive antipsychotic medication during the trial against randomisation; however, the numbers were the same in both groups. We thus assessed this study as some concerns for the domain deviations from intended interventions. </p> <p>In <a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a> and <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>, many participants randomised to the CBT without antipsychotics group received antipsychotics (30.8% in COMPARE and 33.3% in MAPS). This deviation from intended intervention was not balanced between groups, because fewer participants randomised to receive antipsychotics started to receive CBT during the trial (4% in COMPARE and 11% in MAPS). We thus assessed this study as high risk of bias for this domain. </p> <p><a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a> was triple‐blind (participants, clinicians, and outcome assessors), therefore according to the RoB 2 algorithm deviations from intended interventions do not represent a problem, and we assessed this domain as low risk of bias. </p> </section> <section id="CD015332-sec-0119"> <h3 class="title" id="CD015332-sec-0119">Effects of interventions</h3> <p>See: <a href="./full#CD015332-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ CBT without antipsychotics compared to no specific treatment for schizophrenia</a>; <a href="./full#CD015332-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ CBT without antipsychotics compared to antipsychotics for schizophrenia</a>; <a href="./full#CD015332-tbl-0003"><b>Summary of findings 3</b> Summary of findings table ‐ CBT without antipsychotics compared to CBT plus antipsychotics for schizophrenia</a> </p> <p>See <a href="./full#CD015332-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD015332-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD015332-tbl-0003">summary of findings Table 3</a>, and forest plots for detailed results. </p> <section id="CD015332-sec-0120"> <h4 class="title">Comparison 1: CBT versus no specific treatment</h4> <p>For a correct interpretation of the results, it must be considered that about 27% of participants in the CBT arm of the study included in this comparison also received antipsychotics during the study, against randomisation. The same percentage of participants received antipsychotics in the control arm, against randomisation. For details, see <a href="#CD015332-tbl-0004">Table 1</a>. </p> <div class="table" id="CD015332-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Numbers of participants receiving antipsychotic medication during the trial</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CBT</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CBT plus antipsychotics</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Antipsychotics</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No specific treatment</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Francey 2020 – STAGES</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/41 (46.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morrison 2018 – COMPARE</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/26 (30.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/25 (72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/24 (66.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morrison 2020 – MAPS</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/18 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/21 (57.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/22 (72.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morrison 2014 – ACTION</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/37 (27%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/37 (27%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CBT: cognitive behavioural therapy</p> </div> </div> <section id="CD015332-sec-0121"> <h5 class="title">Primary outcome</h5> <section id="CD015332-sec-0122"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0123"> <p><b>1.1 General</b></p> <p><i>1.1.1 Mean endpoint or change score on general mental state scale</i> </p> <p>One study provided data on this outcome. Results did not show a difference between CBT and no specific treatment on mental state measured with PANSS at up to 6 months and after 1 year (up to 6 months: mean difference (MD) −6.99, 95% confidence interval (CI) −14.91 to 0.93, 1 RCT, n = 42; up to 12 months: MD −9.77, 95% CI −20.59 to 1.05, 1 RCT, n = 39, low−certainty evidence). At over one year, CBT without antipsychotics was associated with a reduction in PANSS scores compared to no specific treatment (MD −14.77, 95% CI −27.75 to −1.79, 1 RCT, n = 34). No difference emerged between time points (test for subgroup differences P = 0.60) (<a href="./references#CD015332-fig-0002" title="">Analysis 1.1</a>). </p> </section> </section> </section> <section id="CD015332-sec-0124"> <h5 class="title">Secondary outcomes</h5> <section id="CD015332-sec-0125"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0126"> <p><b>1.1 General</b></p> <p><i>1.1.1 Number of participants with clinically important change in general mental state</i> </p> <p>One study provided data on this outcome. Results did not show a difference between CBT and no specific treatment on number of participants with clinically important change in general mental state (up to 12 months: risk ratio (RR) 2.33, 95% CI 0.65 to 8.34, 1 RCT, n = 74; &gt; 1 year: RR 2.33, 95% CI 0.65 to 8.34, 1 RCT, n = 74) (<a href="./references#CD015332-fig-0003" title="">Analysis 1.2</a>). </p> </section> <section id="CD015332-sec-0127"> <p><b>1.2 Specific</b></p> <p><i>1.2.1 Mean endpoint or change score on positive symptoms scale</i> </p> <p>Based on one study, results did not show a difference between CBT and no specific treatment on positive symptoms measured with PANSS positive (up to 6 months: MD −1.28, 95% CI −4.23 to 1.67, 1 RCT, n = 42; up to 12 months: MD −2.30, 95% CI −6.52 to 1.92, 1 RCT, n = 40; &gt; 1 year: MD −4.20, 95% CI −8.56 to 0.16, n = 37). No difference emerged between time points (test for subgroup differences P = 0.55) (<a href="./references#CD015332-fig-0004" title="">Analysis 1.3</a>). </p> <p><i>1.2.2 Mean endpoint or change score on negative symptoms scale</i> </p> <p>One study provided data on this outcome. Results did not show a difference between CBT and no specific treatment on negative symptoms measured with PANSS negative up to 6 months (up to 6 months: MD −1.47, 95% CI −3.72 to 0.78, 1 RCT, n = 42). At later time points, CBT without antipsychotics was associated with a reduction in negative symptoms (up to 12 months: MD −3.34, 95% CI −6.53 to −0.15, 1 RCT, n = 39; &gt; 1 year: MD −4.06, 95% CI −7.50 to −0.62, n = 34). Test for subgroup differences did not show a difference between time points (P = 0.39) (<a href="./references#CD015332-fig-0005" title="">Analysis 1.4</a>). </p> <p><i>1.2.3 Mean endpoint or change score on depressive symptoms scale</i> </p> <p>Based on one study, results did not show a difference between CBT and no specific treatment on depressive symptoms measured with BDI at any of the analysed time points (up to 6 months: MD 0.20, 95% CI −2.80 to 3.20, 1 RCT, n = 40; up to 12 months: MD 0.44, 95% CI −2.94 to 3.82, 1 RCT, n = 35; &gt; 1 year: MD −1.88, 95% CI −5.62 to 1.86, n = 32). Test for subgroup differences did not show a difference between time points (P = 0.32) (<a href="./references#CD015332-fig-0006" title="">Analysis 1.5</a>). </p> <p><i>1.2.4 Mean endpoint or change score on anxiety symptoms scale</i> </p> <p>One study provided data on this outcome. Results did not show a difference between CBT and no specific treatment on anxiety symptoms measured with BAI (Beck Anxiety Inventory) at any of the analysed time points (up to 6 months: MD −3.15, 95% CI −13.34 to 7.04, 1 RCT, n = 37; up to 12 months: MD −11.86, 95% CI −25.61 to 1.89, 1 RCT, n = 29; &gt; 1 year: MD −12.75, 95% CI −26.32 to 0.82, n = 32). Test for subgroup differences did not show a difference between time points (P = 0.44) (<a href="./references#CD015332-fig-0007" title="">Analysis 1.6</a>). </p> </section> </section> <section id="CD015332-sec-0128"> <h6 class="title">2. Global state</h6> <section id="CD015332-sec-0129"> <p><b>2.1 Relapse/exacerbations of psychosis</b></p> <p>One study provided data on this outcome. Results did not show a difference between CBT and no specific treatment on relapse/exacerbations of psychosis at any of the analysed time points (up to 12 months: RR 3.00, 95% CI 0.13 to 71.34, 1 RCT, n = 74; &gt; 1 year: RR 0.5, 95% CI 0.05 to 5.28, n = 74, low‐certainty evidence). Test for subgroup differences did not show a difference between time points (P = 0.37) (<a href="./references#CD015332-fig-0008" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD015332-sec-0130"> <h6 class="title">3. Service use</h6> <section id="CD015332-sec-0131"> <p><b>3.1 Readmission to hospital</b></p> <p>Based on one study, results did not show a significant difference between CBT and no specific treatment on readmission to hospital up to 12 months (RR 1.00, 95% CI 0.27 to 3.70, 1 RCT, n = 74) (<a href="./references#CD015332-fig-0009" title="">Analysis 1.8</a>). </p> </section> <section id="CD015332-sec-0132"> <p><b>3.2 Number of days in hospital</b></p> <p>Based on data from one study, CBT is associated with a lower number of days in hospital compared to no specific treatment (up to 12 months: MD −22.45, 95% CI −28.82 to −16.08, 1 RCT, n = 74) (<a href="./references#CD015332-fig-0010" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD015332-sec-0133"> <h6 class="title">4. Leaving the study early</h6> <section id="CD015332-sec-0134"> <p><b>4.1 For any reason – overall acceptability</b></p> <p>One study provided data on this outcome. There was no evidence of a difference between CBT and no specific treatment in leaving the study early for any reason at any of the analysed time points (up to 6 months: RR 1.33, 95% CI 0.32 to 5.55, 1 RCT, n = 74; up to 12 months: RR 0.80, 95% CI 0.23 to 2.75, 1 RCT, n = 74, low‐certainty evidence; &gt; 1 year: RR 2.50, 95% CI 0.52 to 12.08). No differences emerged between time points (P = 0.53) (<a href="./references#CD015332-fig-0011" title="">Analysis 1.10</a>). </p> </section> </section> <section id="CD015332-sec-0135"> <h6 class="title">5. Functioning</h6> <section id="CD015332-sec-0136"> <p><b>5.1 Mean endpoint or change score on functioning scale</b></p> <p>One study provided data on this outcome. Results did not show a difference between CBT and no specific treatment in functioning measured with PSP at up to six months (MD −7.85, 95% CI −18.13 to 2.43, 1 RCT, n = 42) and after more than one year (MD −8.80, 95% CI −21.86 to 4.26, 1 RCT, n = 37). CBT without antipsychotics was associated with better functioning at up to 12 months (MD −12.42, 95% CI −22.75 to −2.09, 1 RCT, n = 40, low‐certainty evidence). No differences emerged between the different time points (P = 0.82) (<a href="./references#CD015332-fig-0012" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD015332-sec-0137"> <h6 class="title">6. Cognitive functioning</h6> <p>No study provided data for this outcome.</p> </section> <section id="CD015332-sec-0138"> <h6 class="title">7. Quality of life</h6> <p>No study provided data for this outcome.</p> </section> <section id="CD015332-sec-0139"> <h6 class="title">8. Satisfaction with care</h6> <p>No study provided data for this outcome.</p> </section> <section id="CD015332-sec-0140"> <h6 class="title">9. Behaviour</h6> <section id="CD015332-sec-0141"> <p><b>9.1 Suicide attempts</b></p> <p>Based on one study, results did not show a difference between CBT and no specific treatment in suicide attempts at up to 12 months (RR 1.00, 95% CI 0.06 to 15.40, 1 RCT, n = 74) (<a href="./references#CD015332-fig-0013" title="">Analysis 1.12</a>). </p> </section> </section> <section id="CD015332-sec-0142"> <h6 class="title">10. Adverse events</h6> <section id="CD015332-sec-0143"> <p><b>10.1 Deterioration of symptoms</b></p> <p>One study provided data on this outcome. Results did not show a difference between CBT and no specific treatment in deterioration of symptoms at any time point (up to 12 months: RR 1.00, 95% CI 0.15 to 6.73, 1 RCT, n = 74; &gt; 1 year: RR 0.50, 95% CI 0.10 to 2.56, 1 RCT, n = 74). There was no difference between time points (P = 0.59) (<a href="./references#CD015332-fig-0014" title="">Analysis 1.13</a>). </p> </section> <section id="CD015332-sec-0144"> <p><b>10.2 Participants with serious adverse event</b></p> <p>Based on one study, results did not show a difference between CBT and no specific treatment in serious adverse events (up to 12 months: RR 0.33, 95% CI 0.07 to 1.54, 1 RCT, n = 74) (<a href="./references#CD015332-fig-0015" title="">Analysis 1.14</a>). </p> </section> </section> <section id="CD015332-sec-0145"> <h6 class="title">11. Mortality</h6> <section id="CD015332-sec-0146"> <p><b>11.1 Overall mortality</b></p> <p>One study provided data on this outcome. There was no evidence of a difference between CBT and no specific treatment in overall mortality at any time point (up to 12 months: RR 0.33, 95% CI 0.01 to 7.93, 1 RCT, n = 74; &gt; 1 year: RR 0.20, 95% CI 0.01 to 4.03, n = 74). There was no difference between time points (P = 0.82) (<a href="./references#CD015332-fig-0016" title="">Analysis 1.15</a>). </p> </section> <section id="CD015332-sec-0147"> <p><b>11.2 Mortality due to natural causes</b></p> <p>One study provided data on this outcome. There was no evidence of a difference between CBT and no specific treatment in mortality due to natural causes at any time point (up to 12 months: RR 0.20, 95% CI 0.01 to 4.03, 1 RCT, n = 74; &gt; 1 year: RR 0.11, 95% CI 0.01 to 1.99, n = 74). There was no difference between time points (P = 0.78) (<a href="./references#CD015332-fig-0017" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD015332-sec-0148"> <h6 class="title">12. Economic outcomes</h6> <p>No study provided data for this outcome.</p> </section> </section> </section> <section id="CD015332-sec-0149"> <h4 class="title">Comparison 2: CBT versus antipsychotics</h4> <p>For a correct interpretation of the results, it must be considered that about 32% participants in the CBT arms of the studies included in this comparison also received antipsychotics during the studies, against randomisation. For details, see <a href="#CD015332-tbl-0004">Table 1</a>. </p> <section id="CD015332-sec-0150"> <h5 class="title">Primary outcome</h5> <section id="CD015332-sec-0151"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0152"> <p><b>1.1 General</b></p> <p><i>1.1.1 Mean endpoint or change score on general mental state scale</i> </p> <p>Two studies provided data on this outcome. Results did not show a difference between CBT and antipsychotics on mental state measured with PANSS at any of the predefined examined time points (up to 6 months: MD −3.75, 95% CI −11.61 to 4.12, I<sup>2</sup> = 39% (not important to moderate heterogeneity), 2 RCTs, n = 78; up to 12 months: MD 3.38, 95% CI −2.38 to 9.14, I<sup>2</sup> = 0%, 2 RCTs, n = 63, very low‐certainty evidence). No differences emerged between time points (test for subgroup differences P = 0.15) (<a href="./references#CD015332-fig-0018" title="">Analysis 2.1</a>). </p> </section> </section> </section> <section id="CD015332-sec-0153"> <h5 class="title">Secondary outcomes</h5> <section id="CD015332-sec-0154"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0155"> <p><b>1.1 General</b></p> <p><i>1.1.1 Clinically important change in general mental state</i> </p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and antipsychotics in number of participants with a clinically important change in general mental state at any of the analysed time points (up to 6 months: RR 1.15, 95% CI 0.44 to 2.98, I<sup>2</sup> = 0%, 2 RCTs, n = 90; up to 12 months: RR 0.90, 95% CI 0.36 to 2.28, I<sup>2</sup> = 0%, 2 RCTs, n = 90). No differences emerged between time points (test for subgroup differences P = 0.72) (<a href="./references#CD015332-fig-0019" title="">Analysis 2.2</a>). </p> </section> <section id="CD015332-sec-0156"> <p><b>1.2 Specific</b></p> <p><i>1.2.1 Mean endpoint or change score on positive symptoms scale</i> </p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and antipsychotics in positive symptoms measured with PANSS positive at any of the analysed time points (up to 6 months: MD 0.25, 95% CI −3.08 to 3.58, I<sup>2</sup> = 0%, 2 RCTs, n = 77; up to 12 months: MD 1.96, 95% CI −2.80 to 6.73, I<sup>2</sup> = 62% (substantial heterogeneity), 2 RCTs, n = 63). No differences emerged between time points (test for subgroup differences P = 0.56) (<a href="./references#CD015332-fig-0020" title="">Analysis 2.3</a>). </p> <p><i>1.2.2 Mean endpoint or change score on negative symptoms scale</i> </p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and antipsychotics in negative symptoms measured with PANSS negative at any of the analysed time points (up to 6 months: MD −1.19, 95% CI −5.27 to 2.89, I<sup>2</sup> = 67% (substantial heterogeneity), 2 RCTs, n = 78; up to 12 months: MD 0.54, 95% CI −2.63 to 3.71, I<sup>2</sup> = 46% (moderate heterogeneity), 2 RCTs, n = 63). No differences emerged between time points (test for subgroup differences P = 0.51) (<a href="./references#CD015332-fig-0021" title="">Analysis 2.4</a>). </p> <p><i>1.2.3 Mean endpoint or change score on depressive symptoms scale</i> </p> <p>Two studies provided data on this outcome. Results did not show a difference between CBT and antipsychotics in depressive symptoms measured with HADS depression at any of the analysed time points (up to 6 months: MD −1.75, 95% CI −4.27 to 0.77, I<sup>2</sup> = 0%, 2 RCTs, n = 59; up to 12 months: MD −0.68, 95% CI −3.08 to 1.73, I<sup>2</sup> = 0%, 2 RCTs, n = 54). No differences emerged between time points (test for subgroup differences P = 0.55) (<a href="./references#CD015332-fig-0022" title="">Analysis 2.5</a>). </p> <p><i>1.2.4 Mean endpoint or change score on anxiety symptoms scale</i> </p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and antipsychotics in symptoms of anxiety measured with HADS anxiety at any of the analysed time points (up to 6 months: MD −1.30, 95% CI −4.02 to 1.43, I<sup>2</sup> = 0%, 2 RCTs, n = 60; up to 12 months: MD −1.34, 95% CI −3.77 to 1.09, I<sup>2</sup> = 0%, 2 RCTs, n = 54). No differences emerged between time points (test for subgroup differences P = 0.98) (<a href="./references#CD015332-fig-0023" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD015332-sec-0157"> <h6 class="title">2. Global state</h6> <section id="CD015332-sec-0158"> <p><b>2.1 Relapse/exacerbations of psychosis</b></p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and antipsychotics in relapse or exacerbations of psychosis at any of the analysed time points (up to 6 months: RR 2.35, 95% CI 0.36 to 15.31, I<sup>2</sup> = 0%, 2 RCTs, n = 90; up to 12 months: RR 2.78, 95% CI 0.12 to 65.08, I<sup>2</sup> = 0%, 2 RCTs, n = 90, very low‐certainty evidence). No differences emerged between time points (test for subgroup differences P = 0.93) (<a href="./references#CD015332-fig-0024" title="">Analysis 2.7</a>). </p> </section> <section id="CD015332-sec-0159"> <p><b>2.2 Mean endpoint or change score on global state scale</b></p> <p>One study provided data on this outcome. No difference was shown between CBT and antipsychotics in CGI‐Clinician endpoint scores at any of the analysed time points (up to 6 months: MD 0.13, 95% CI −0.49 to 0.75, 1 RCT, n = 44; up to 12 months: MD 0.15, 95% CI −0.50 to 0.80, 1 RCT, n = 43). No differences emerged between time points (test for subgroup differences P = 0.97). Similar results were obtained by CGI‐Improvement (up to 6 months: MD −0.17, 95% CI −0.89 to 0.55, 1 RCT, n = 44; up to 12 months: MD 0.05, 95% CI −0.57 to 0.67, 1 RCT, n = 42). Test for subgroup differences did not reveal a difference between time points (P = 0.65) (<a href="./references#CD015332-fig-0025" title="">Analysis 2.8</a>; <a href="./references#CD015332-fig-0026" title="">Analysis 2.9</a>). </p> </section> </section> <section id="CD015332-sec-0160"> <h6 class="title">3. Service use</h6> <section id="CD015332-sec-0161"> <p><b>3.1 Readmission to hospital</b></p> <p>Two studies provided data on this outcome. In one study, no participants were readmitted to the hospital at up to six months. In the other study, three participants in the CBT group and zero participants in the antipsychotics group were readmitted to the hospital (up to 12 months: RR 6.48, 95% CI 0.35 to 119.32, 1 RCT, n = 50) (<a href="./references#CD015332-fig-0027" title="">Analysis 2.10</a>). </p> </section> <section id="CD015332-sec-0162"> <p><b>3.2 Number of days in hospital</b></p> <p>One study provided data on this outcome. Mean number of days in hospital was 50 in the CBT arm and 0 in the standard care (including antipsychotics) arm. It was not possible to estimate a mean difference (<a href="./references#CD015332-fig-0028" title="">Analysis 2.11</a>). </p> </section> </section> <section id="CD015332-sec-0163"> <h6 class="title">4. Leaving the study early</h6> <section id="CD015332-sec-0164"> <p><b>4.1 For any reason – overall acceptability</b></p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and antipsychotics in leaving study early for any reason at any of the analysed time points (up to 6 months: RR 1.66, 95% CI 0.21 to 12.94, I<sup>2</sup> = 0%, 2 RCTs, n = 90; up to 12 months: RR 1.66, 95% CI 0.21 to 12.94, I<sup>2</sup> = 0%, 2 RCTs, n = 90, very low‐certainty evidence). No differences emerged between time points (test for subgroup differences P = 1.00) (<a href="./references#CD015332-fig-0029" title="">Analysis 2.12</a>). </p> </section> </section> <section id="CD015332-sec-0165"> <h6 class="title">5. Functioning</h6> <section id="CD015332-sec-0166"> <p><b>5.1 Mean endpoint or change score on functioning scale</b></p> <p>Two studies provided data on this outcome. Results did not show a difference between CBT and antipsychotics in functioning (measured with PSP and FESFS scales) (up to 6 months: standardised mean difference (SMD) 0.18, 95% CI −0.37 to 0.72, I<sup>2</sup> = 0%, 2 RCTs, n = 53; up to 12 months: SMD −0.03, 95% CI −0.61 to 0.55, I<sup>2</sup> = 0%, 2 RCTs, n = 46, very low‐certainty evidence). No differences emerged between time points (test for subgroup differences P = 0.92) (<a href="./references#CD015332-fig-0032" title="">Analysis 2.15</a>). </p> </section> </section> <section id="CD015332-sec-0167"> <h6 class="title">6. Cognitive functioning</h6> <p>No study reported data on this outcome.</p> </section> <section id="CD015332-sec-0168"> <h6 class="title">7. Quality of life</h6> <section id="CD015332-sec-0169"> <p><b>7.1 Mean endpoint or change score on quality of life scale</b></p> <p>Based on two studies, results did not show a difference between CBT and antipsychotics in quality of life (measured with WHOQOL and EQ‐5D‐5L at any of the predefined time points (up to 6 months: SMD 0.11, 95% CI −0.42 to 0.64, I<sup>2</sup> = 0%, 2 RCTs, n = 56; up to 12 months: SMD −0.09, 95% CI −0.64 to 0.46, I<sup>2</sup> = 0%, 2 RCTs, n = 51). No differences emerged between time points (test for subgroup differences P = 0.61) (<a href="./references#CD015332-fig-0035" title="">Analysis 2.18</a>). </p> </section> </section> <section id="CD015332-sec-0170"> <h6 class="title">8. Satisfaction with care</h6> <p>No study reported data on this outcome.</p> </section> <section id="CD015332-sec-0171"> <h6 class="title">9. Behaviour</h6> <section id="CD015332-sec-0172"> <p><b>9.1 Violent incidents</b></p> <p>Two studies provided data on this outcome. No difference was found between CBT and antipsychotics in violent incidents (up to 12 months: RR 1.22, 95% CI 0.19 to 7.84, 2 RCTs, n = 90) (<a href="./references#CD015332-fig-0036" title="">Analysis 2.19</a>). </p> </section> <section id="CD015332-sec-0173"> <p><b>9.2 Self‐injury</b></p> <p>Two studies provided data on this outcome. No difference was found between CBT and antipsychotics in self‐injury (up to 12 months: RR 1.05, 95% CI 0.43 to 2.56, 2 RCTs, n = 90) (<a href="./references#CD015332-fig-0037" title="">Analysis 2.20</a>). </p> </section> <section id="CD015332-sec-0174"> <p><b>9.3 Suicide attempts</b></p> <p>Based on one study, results did not show a difference between CBT and antipsychotics in suicide attempts (up to 12 months: RR 3.63, 95% CI 0.16 to 84.11, 1 RCT, n = 40) (<a href="./references#CD015332-fig-0038" title="">Analysis 2.21</a>). </p> </section> </section> <section id="CD015332-sec-0175"> <h6 class="title">10. Adverse events</h6> <section id="CD015332-sec-0176"> <p><b>10.1 Participants with at least one adverse event</b></p> <p>Based on one study, results did not show a difference between CBT and antipsychotics in number of participants experiencing at least one adverse event (up to 12 months: RR 0.47, 95% CI 0.21 to 1.07, 1 RCT, n = 40, very low‐certainty evidence) (<a href="./references#CD015332-fig-0039" title="">Analysis 2.22</a>). </p> </section> <section id="CD015332-sec-0177"> <p><b>10.2 Participants with at least one serious adverse event</b></p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and antipsychotics in number of participants experiencing at least one serious adverse event (up to 12 months: RR 2.83, 95% CI 0.80 to 10.05, I<sup>2</sup> = 0%, 2 RCTs, n = 90) (<a href="./references#CD015332-fig-0040" title="">Analysis 2.23</a>). </p> </section> <section id="CD015332-sec-0178"> <p><b>10.3 Deterioration of symptoms</b></p> <p>Two studies provided data on this outcome. Results did not show a difference between CBT and antipsychotics in deterioration of symptoms at any of the analysed time points (up to 6 months: RR 2.13, 95% CI 0.41 to 11.02, I<sup>2</sup> = 0%, 2 RCTs, n = 90; up to 12 months: RR 0.46, 95% CI 0.04 to 4.77, 2 RCTs, n = 90). Test for subgroup differences did not show a difference between time points (P = 0.29) (<a href="./references#CD015332-fig-0041" title="">Analysis 2.24</a>). </p> </section> <section id="CD015332-sec-0179"> <p><b>10.4 Mean endpoint or change score on adverse event scale</b></p> <p>Two studies provided data on this outcome. CBT was associated with fewer adverse events in ANNSERS (Antipsychotic Non‐Neurological Side Effects Rating Scale) endpoint scores compared to antipsychotics at all of the analysed time points (up to 6 months: MD −4.94, 95% CI −8.60 to −1.28, I<sup>2</sup> = 0%, 2 RCTs, n = 48; up to 12 months: MD −6.96, 95% CI −11.55 to −2.37, I<sup>2</sup> = 0%, 2 RCTs, n = 42) (<a href="./references#CD015332-fig-0042" title="">Analysis 2.25</a>). </p> </section> </section> <section id="CD015332-sec-0180"> <h6 class="title">11. Mortality</h6> <p>No study reported data on this outcome.</p> </section> <section id="CD015332-sec-0181"> <h6 class="title">12. Economic outcomes</h6> <p>No study reported data on this outcome.</p> </section> </section> </section> <section id="CD015332-sec-0182"> <h4 class="title">Comparison 3: CBT versus CBT plus antipsychotics</h4> <p>For a correct interpretation of the results, it must be considered that, on average, about 39% of the participants in the CBT arms of the studies included in this comparison also received antipsychotics during the studies, against randomisation. For details, see <a href="#CD015332-tbl-0004">Table 1</a>. </p> <section id="CD015332-sec-0183"> <h5 class="title">Primary outcome</h5> <section id="CD015332-sec-0184"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0185"> <p><b>1.1 General</b></p> <p><i>1.1.1 Mean endpoint or change score on general mental state scale</i> </p> <p>Three studies provided data on this outcome. Results did not show a difference between CBT and CBT plus antipsychotics on mental state measured with PANSS or BPRS at any of the prespecified time points (up to 6 months: SMD 0.20, 95% CI −0.21 to 0.60, I<sup>2</sup> = 31% (not important heterogeneity), 3 RCTs, n = 143; up to 12 months: SMD 0.30, 95% CI −0.06 to 0.65, I<sup>2</sup> = 0%, 3 RCTs, n = 125, very low‐certainty evidence; &gt; 1 year: SMD 0.22, 95% CI −0.32 to 0.76, 1 RCT, n = 55) (<a href="./references#CD015332-fig-0045" title="">Analysis 3.3</a>). No differences emerged between time points (test for subgroup differences P = 0.93). </p> </section> </section> </section> <section id="CD015332-sec-0186"> <h5 class="title">Secondary outcomes</h5> <section id="CD015332-sec-0187"> <h6 class="title">1. Mental state</h6> <section id="CD015332-sec-0188"> <p><b>1.1 General</b></p> <p><i>1.1.1 Clinically important change in general mental state</i> </p> <p>Two studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in number of participants with a clinically important change in general mental state at any of the analysed time points (up to 6 months: RR 0.62, 95% CI 0.15 to 2.53, I<sup>2</sup> = 59% (moderate heterogeneity), 2 RCTs, n = 90; up to 12 months: RR 0.80, 95% CI 0.33 to 1.98, I<sup>2</sup> = 0%, 2 RCTs, n = 90) (<a href="./references#CD015332-fig-0046" title="">Analysis 3.4</a>). No differences emerged between time points (test for subgroup differences P = 0.76). </p> </section> <section id="CD015332-sec-0189"> <p><b>1.2 Specific</b></p> <p><i>1.2.1 Mean endpoint or change score on positive symptoms scale</i> </p> <p>Three studies provided data on this outcome. CBT plus antipsychotics was associated with a greater reduction in positive symptoms (PANSS and BPRS scales) up to 12 months, but not at up to 6 months (up to 6 months: SMD 0.22, 95% CI −0.19 to 0.64, I<sup>2</sup> = 35% (moderate heterogeneity), 3 RCTs, n = 146; up to 12 months: SMD 0.40, 95% CI 0.05 to 0.76, I<sup>2</sup> = 0%, 3 RCTs, n = 126). Test for subgroup differences confirmed a difference between time points (P = 0.03) (<a href="./references#CD015332-fig-0049" title="">Analysis 3.7</a>). </p> <p><i>1.2.2 Mean endpoint or change score on negative symptoms scale</i> </p> <p>Three studies provided data on this outcome. Results showed a trend in favour of CBT plus antipsychotics in terms of reduction of negative symptoms (PANSS and SANS scales) at up to 12 months, but the CI does not exclude the possibility of no difference with CBT (up to 6 months: SMD 0.10, 95% CI −0.36 to 0.55, I<sup>2</sup> = 46% (moderate heterogeneity), 3 RCTs, n = 143; up to 12 months: SMD 0.40, 95% CI −0.01 to 0.81, I<sup>2</sup> = 20% (not important heterogeneity), 3 RCTs, n = 123). No differences emerged between time points (test for subgroup differences P = 0.33) (<a href="./references#CD015332-fig-0052" title="">Analysis 3.10</a>). </p> <p><i>1.2.3 Mean endpoint or change score on depressive symptoms scale</i> </p> <p>Three studies provided data on this outcome. There was no evidence of a difference between CBT and CBT plus antipsychotics in depressive symptoms (HADS depression) in mental state at any time points (up to 6 months: SMD 0.18, 95% CI −0.18 to 0.54, I<sup>2</sup> = 0%, 3 RCTs, n = 123; up to 12 months: SMD 0.16, 95% CI −0.22 to 0.54, I<sup>2</sup> = 0%, 3 RCTs, n = 108). Test for subgroup differences did not show a difference between time points (P = 0.94) (<a href="./references#CD015332-fig-0055" title="">Analysis 3.13</a>). </p> <p><i>1.2.4 Mean endpoint or change score on anxiety symptoms scale</i> </p> <p>Three studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in anxiety symptoms (HADS anxiety) at any time points (up to 6 months: SMD 0.03, 95% CI −0.37 to 0.43, I<sup>2</sup> = 17% (not important heterogeneity), 3 RCTs, n = 125; up to 12 months: SMD 0.21, 95% CI −0.17 to 0.59, I<sup>2</sup> = 0%, 3 RCTs, n = 109; &gt; 1 year: SMD 0.23, 95% CI −0.31 to 0.77, 1 RCT, n = 55). Test for subgroup differences did not show a difference between time points (P = 0.76) (<a href="./references#CD015332-fig-0058" title="">Analysis 3.16</a>). </p> </section> </section> <section id="CD015332-sec-0190"> <h6 class="title">2. Global state</h6> <section id="CD015332-sec-0191"> <p><b>2.1 Relapse/exacerbations of psychosis</b></p> <p>Two studies provided data on this outcome. There was no evidence of a difference between CBT and CBT plus antipsychotics in relapse or exacerbations of psychosis at any of the analysed time points (up to 6 months: RR 2.21, 95% CI 0.30 to 16.35, I<sup>2</sup> = 0%, 2 RCTs, n = 90; up to 12 months: RR 2.89, 95% CI 0.12 to 67.75, 1 RCT, n = 90, very low‐certainty evidence). No differences emerged between time points (test for subgroup differences P = 0.89) (<a href="./references#CD015332-fig-0059" title="">Analysis 3.17</a>). </p> </section> <section id="CD015332-sec-0192"> <p><b>2.2 Mean endpoint or change score on global state scale</b></p> <p>Only one study used CGI and CGI‐Improvement scales. Results showed a trend in favour of CBT plus antipsychotics in mean endpoint scores on global state scales at up to six months, although the CI does not exclude the possibility of no difference (CGI‐Clinician: up to 6 months: MD 0.59, 95% CI −0.00 to 1.18, 1 RCT, n = 43; up to 12 months: MD 0.38, 95% CI −0.28 to 1.04, 1 RCT, n = 41). No differences emerged between time points (test for subgroup differences P = 0.64) (<a href="./references#CD015332-fig-0060" title="">Analysis 3.18</a>). Results of CGI‐Improvement showed a similar pattern (up to 6 months: MD 0.64, 95% CI −0.00 to 1.28, 1 RCT, n = 43; up to 12 months: MD 0.25, 95% CI −0.41 to 0.91, 1 RCT, n = 40). No differences emerged between time points (test for subgroup differences P = 0.41) (<a href="./references#CD015332-fig-0061" title="">Analysis 3.19</a>). </p> </section> </section> <section id="CD015332-sec-0193"> <h6 class="title">3. Service use</h6> <section id="CD015332-sec-0194"> <p><b>3.1 Readmission to hospital</b></p> <p>One study provided data on this outcome. There was no evidence of a difference between CBT and CBT plus antipsychotics in readmission to hospital (up to 6 months: RR 0.39, 95% CI 0.02 to 8.93, 1 RCT, n = 39; up to 12 months: RR 0.64, 95% CI 0.12 to 3.52, 1 RCT, n = 51). No differences emerged between time points (test for subgroup differences P = 0.78) (<a href="./references#CD015332-fig-0062" title="">Analysis 3.20</a>). </p> </section> <section id="CD015332-sec-0195"> <p><b>3.2 Number of days in hospital</b></p> <p>One study provided data on this outcome. No difference was shown between CBT and CBT plus antipsychotics in number of days in hospital (up to 12 months: RR 7.75, 95% CI −26.53 to 42.03, 1 RCT, n = 41) (<a href="./references#CD015332-fig-0063" title="">Analysis 3.21</a>). </p> </section> </section> <section id="CD015332-sec-0196"> <h6 class="title">4. Leaving the study early</h6> <section id="CD015332-sec-0197"> <p><b>4.1 For any reason – overall acceptability</b></p> <p>Three studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in leaving the study early for any reason at any of the analysed time points (up to 6 months: RR 0.82, 95% CI 0.59 to 1.14, I<sup>2</sup> = 0%, 3 RCTs, n = 180; up to 12 months: RR 0.70, 95% CI 0.12 to 4.11, I<sup>2</sup> = 0%, 2 RCTs, n = 90, very low‐certainty evidence). Test for subgroup differences did not show a difference between time points (P = 0.87) (<a href="./references#CD015332-fig-0064" title="">Analysis 3.22</a>). </p> </section> <section id="CD015332-sec-0198"> <p><b>4.2 Due to adverse events</b></p> <p>One study provided data on this outcome. There was no evidence of a difference between CBT and CBT plus antipsychotics in leaving the study early due to adverse events up to six months (RR 0.19, 95% CI 0.01 to 3.88, 1 RCT, n = 100) (<a href="./references#CD015332-fig-0065" title="">Analysis 3.23</a>). </p> </section> </section> <section id="CD015332-sec-0199"> <h6 class="title">5. Functioning</h6> <section id="CD015332-sec-0200"> <p><b>5.1 Mean endpoint or change score on functioning scale</b></p> <p>Three studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in functioning (PSP, FESFS, and SOFAS scales) at any of the analysed time points (up to 6 months: SMD 0.06, 95% CI −0.30 to 0.42, I<sup>2</sup> = 0%, 3 RCTs, n = 119; up to 12 months: SMD 0.13, 95% CI −0.25 to 0.50, I<sup>2</sup> = 0%, 3 RCTs, n = 110, very low‐certainty evidence; &gt; 1 year: SMD 0.27, 95% CI −0.27 to 0.81, 1 RCT, n = 56). Test for subgroup differences did not show a difference between time points (P = 0.81) (<a href="./references#CD015332-fig-0069" title="">Analysis 3.27</a>). </p> </section> </section> <section id="CD015332-sec-0201"> <h6 class="title">6. Cognitive functioning</h6> <p>No studies reported data on this outcome.</p> </section> <section id="CD015332-sec-0202"> <h6 class="title">7. Quality of life</h6> <section id="CD015332-sec-0203"> <p><b>7.1 Mean endpoint or change score on quality of life scale</b></p> <p>Three studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in quality of life (WHOQOL, EQ‐5D‐5L, and QLS) at any of the analysed time points (up to 6 months: SMD 0.37, 95% CI −0.11 to 0.85, I<sup>2</sup> = 32% (not important to moderate heterogeneity), 3 RCTs, n = 116; up to 12 months: SMD 0.17, 95% CI −0.21 to 0.56, I<sup>2</sup> = 0%, 3 RCTs, n = 106; &gt; 1 year: SMD 0.15, 95% CI −0.40 to 0.70, 1 RCT, n = 52). No differences emerged between time points (test for subgroup differences P = 0.79) (<a href="./references#CD015332-fig-0073" title="">Analysis 3.31</a>). </p> </section> </section> <section id="CD015332-sec-0204"> <h6 class="title">8. Satisfaction with care</h6> <p>No studies reported data on this outcome.</p> </section> <section id="CD015332-sec-0205"> <h6 class="title">9. Behaviour</h6> <section id="CD015332-sec-0206"> <p><b>9.1 Violent incidents</b></p> <p>Two studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in violent incidents at up to 12 months (RR 1.16, 95% CI 0.18 to 7.54, I<sup>2</sup> = 0%, 2 RCTs, n = 90) (<a href="./references#CD015332-fig-0074" title="">Analysis 3.32</a>). </p> </section> <section id="CD015332-sec-0207"> <p><b>9.2 Self‐injury</b></p> <p>Three studies provided data on this outcome. Results did not show a difference between CBT and CBT plus antipsychotics in self‐injury at any of the analysed time points (up to 6 months: RR 0.82, 95% CI 0.30 to 2.25, 1 RCT, n = 90; up to 12 months: RR 0.55, 95% CI 0.26 to 1.13, I<sup>2</sup> = 0%, 2 RCTs, n = 90). No differences emerged between time points (test for subgroup differences P = 0.52) (<a href="./references#CD015332-fig-0075" title="">Analysis 3.33</a>). </p> </section> <section id="CD015332-sec-0208"> <p><b>9.3 Suicide attempts</b></p> <p>One study provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in suicide attempts at up to 12 months (RR 1.17, 95% CI 0.08 to 17.35, 1 RCT, n = 39) (<a href="./references#CD015332-fig-0076" title="">Analysis 3.34</a>, <a href="./references#CD015332-fig-0077" title="">Analysis 3.35</a>). </p> </section> </section> <section id="CD015332-sec-0209"> <h6 class="title">10. Adverse events</h6> <section id="CD015332-sec-0210"> <p><b>10.1 Participants with at least one adverse event</b></p> <p>Two studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in participants with at least one adverse event at up to six months (RR 1.06, 95% CI 0.78 to 1.43, 1 RCT, n = 90). Results showed that fewer participants had at least one adverse event with CBT without antipsychotics at up to 12 months (RR 0.36, 95% CI 0.17 to 0.80, 1 RCT, n = 39, low‐certainty evidence). Test for subgroup differences confirmed a difference between time points (P = 0.01) (<a href="./references#CD015332-fig-0078" title="">Analysis 3.36</a>). </p> </section> <section id="CD015332-sec-0211"> <p><b>10.2 Participants with at least one serious adverse event</b></p> <p>Three studies provided data on this outcome. There was no evidence of a difference between CBT and CBT plus antipsychotics in participants with serious adverse events at any of the analysed time points (up to 6 months: RR 0.96, 95% CI 0.37 to 2.50, 1 RCT, n = 90; up to 12 months: RR 0.71, 95% CI 0.32 to 1.57, I<sup>2</sup> = 0%, 2 RCTs, n = 100). No differences emerged between time points (test for subgroup differences P = 0.64) (<a href="./references#CD015332-fig-0079" title="">Analysis 3.37</a>). </p> </section> <section id="CD015332-sec-0212"> <p><b>10.3 Deterioration of symptoms</b></p> <p>Three studies provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in deterioration of symptoms at any of the analysed time points (up to 6 months: RR 1.07, 95% CI 0.37 to 3.10, I<sup>2</sup> = 0%, 3 RCTs, n = 180; up to 12 months: RR 1.05, 95% CI 0.11 to 9.74, I<sup>2</sup> = 0%, 2 RCTs, n = 90). No differences emerged between time points (test for subgroup differences P = 0.99) (<a href="./references#CD015332-fig-0080" title="">Analysis 3.38</a>). </p> </section> <section id="CD015332-sec-0213"> <p><b>10.4 Lack of improvement</b></p> <p>One study provided data on this outcome. No difference was found between CBT and CBT plus antipsychotics in lack of improvement up to six months (RR 0.96, 95% CI 0.33 to 2.74, 1 RCT, n = 90) (<a href="./references#CD015332-fig-0081" title="">Analysis 3.39</a>). </p> </section> <section id="CD015332-sec-0214"> <p><b>10.5 Mean endpoint or change score on adverse event scale</b></p> <p>Three studies provided data on this outcome. There was no evidence of a difference between CBT and CBT plus antipsychotics in adverse events measured with ANNSERS scale at any of the analysed time points (up to 6 months: MD −3.68, 95% CI −9.66 to 2.31, I<sup>2</sup> = 73% (substantial heterogeneity), 2 RCTs, n = 52; up to 12 months: MD −3.47, 95% CI −12.06 to 5.11, I<sup>2</sup> = 82% (substantial heterogeneity), 2 RCTs, n = 49). No differences emerged between time points (test for subgroup differences P = 0.97) (<a href="./references#CD015332-fig-0082" title="">Analysis 3.40</a>). </p> <p>Results of UKU scale (UKU Side Effect Rating Scale) did not show a difference between CBT and CBT plus antipsychotics at any of the analysed time points (up to 6 months: MD −1.86, 95% CI −6.37 to 2.66, I<sup>2</sup> = 80% (substantial heterogeneity), 3 RCTs, n = 122; up to 12 months: MD −3.47, 95% CI −12.06 to 5.11, I<sup>2</sup> = 82% (substantial heterogeneity), 2 RCTs, n = 49). No differences emerged between time points (test for subgroup differences P = 0.74) (<a href="./references#CD015332-fig-0083" title="">Analysis 3.41</a>). </p> </section> </section> <section id="CD015332-sec-0215"> <h6 class="title">11. Mortality</h6> <p>No study reported data on this outcome.</p> </section> <section id="CD015332-sec-0216"> <h6 class="title">12. Economic outcomes</h6> <p>No study reported data on this outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015332-sec-0217" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015332-sec-0217"></div> <section id="CD015332-sec-0218"> <h3 class="title" id="CD015332-sec-0218">Summary of main results</h3> <p>Four studies were eligible for inclusion in the review. All four studies (300 participants) provided data for the meta‐analysis. </p> <p>Based on low‐certainty evidence, CBT was associated with a reduction in PANSS total scores (<a href="./references#CD015332-fig-0002" title="">Analysis 1.1</a>) and negative symptoms (<a href="./references#CD015332-fig-0005" title="">Analysis 1.4</a>) at longer than 12 months when compared to no specific treatment. CBT was also associated with a lower duration of hospital stay (<a href="./references#CD015332-fig-0010" title="">Analysis 1.9</a>) and better functioning at up to 12 months (<a href="./references#CD015332-fig-0012" title="">Analysis 1.11</a>). </p> <p>We found no differences between CBT and antipsychotics for any of the investigated outcomes, with the exception of adverse events measured with ANNSERS (<a href="./references#CD015332-fig-0042" title="">Analysis 2.25</a>). </p> <p>Based on very low‐certainty evidence, CBT was less effective than CBT plus antipsychotics in reducing positive symptoms at up to 12 months (<a href="./references#CD015332-fig-0049" title="">Analysis 3.7</a>) and negative symptoms at up to 12 months (even if the CI includes the possibility of no difference) (<a href="./references#CD015332-fig-0052" title="">Analysis 3.10</a>). CBT was also associated with worse global state measured with CGI at up to six months (even if the CI includes the possibility of no difference) (<a href="./references#CD015332-fig-0060" title="">Analysis 3.18</a>), and a lower number of participants experiencing at least one adverse event at up to 12 months (<a href="./references#CD015332-fig-0078" title="">Analysis 3.36</a>). </p> </section> <section id="CD015332-sec-0219"> <h3 class="title" id="CD015332-sec-0219">Overall completeness and applicability of evidence</h3> <p>Despite the high number of systematic reviews and meta‐analyses on CBT for schizophrenia, we could not identify any review specifically focusing on CBT delivered without concomitant antipsychotic medication. </p> <p>This review summarises the available evidence on the provision of CBT without antipsychotics to people with schizophrenia. We followed methodologically robust Cochrane standards in conducting the review, which provides an overall picture of the most relevant outcomes. </p> <p>Caution is advised in the interpretation of results, due to the low number of included studies and the very low number of studies providing data for each outcome (one to three studies). </p> <p>The low number of included studies identified reflects the challenge and controversy surrounding the idea of providing CBT without medication to people with schizophrenia. </p> <p>Indeed, a considerable number of participants in the included studies received antipsychotic treatment against the randomisation plan (about 35% of those in the 'CBT without antipsychotic' study arm) (<a href="#CD015332-tbl-0004">Table 1</a>), reflecting the potential challenges of such an approach in real‐world clinical practice. </p> <p>Moreover, it should be noted that all of the identified studies recruited participants from early intervention for psychosis services (Early Psychosis Prevention and Intervention Centre (EPPIC) in Australia and Early Intervention in Psychosis (EIP) service in the UK) or explicitly with first‐episode psychosis. Indeed, the mean age of the people included in this meta‐analysis was around 22 years. It is therefore questionable whether these results can be generalised to the general population of people with schizophrenia. </p> <p>Additionally, study participants had on average a baseline severity of 80.63 on the PANSS, which corresponds to a moderately ill CGI score (<a href="./references#CD015332-bbs2-0049" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?Schizophrenia Research2005;79:231-38. [DOI: 10.1016/j.schres.2005.04.008]">Leucht 2005</a>). Only in <a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a> were participants markedly ill at baseline. This should also be taken into account when generalising the results. </p> <p>As a methodological limitation, it should be noted that the aim of the included studies was to investigate the feasibility (<a href="./references#CD015332-bbs2-0003" title="ISRCTN06022197. A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis. https://www.isrctn.com/ISRCTN06022197 (first received 20 March 2014). [DOI: 10.1186/ISRCTN06022197]JauharS . Cognitive behavioural therapy – a valid alternative to antipsychotics for psychosis?The Lancet Psychiatry2018;5(5):381-383. [DOI: 10.1016/ S2215-0366(18)30123-8]LawH , CarterL , SellersR , EmsleyR , ByrneR , DaviesL , et al. A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis: Psychological, Social and Integrative Approaches2017;9(3):193-204. [DOI: 10.1080/17522439.2017.1316302]MorrisonA . Psychological interventions for promoting recovery. In: Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller , editors(s). European Archives of Psychiarty and Clinical Neuroscience. Vol. 267. Berlin: European Scientific Association on Schizophrenia and otherPsychoses, 2017:7-8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):411-423. [DOI: 10.1016/S2215-0366(18)30096-8]MorrisonAP , LawH , CarterL , SellersR , EmsleyR , PyleM . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. The Lancet Psychiatry2018;5(5):Supplementary Appendix 1-16. [DOI: 10.1016/S2215-0366(18)30096-8]">Morrison 2018 – COMPARE</a>; <a href="./references#CD015332-bbs2-0004" title="ByrneRE , BirdJC , ReeveS , JonesW , ShiersD , MorrisonAP , et al. Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100417):1-6. [DOI: 10.1016/j.eclinm.2020.100417]ByrneRE , ReeveS , BirdJC , JonesW , ShiersD , MorrisonAP , et al. Clinicians’ views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS). EClinical Medicine2020;24(100421):1-7. [DOI: 10.1016/j.eclinm.2020.100421]ISRCTN80567433. Managing adolescent first episode psychosis: a feasibility study. www.isrctn.com/ISRCTN80567433 (first received 27 February 2017). [DOI: 10.1186/ISRCTN80567433]JauharS . Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?The Lancet Psychiatry2020;7(9):726-728. [DOI: 10.1016/ S2215-0366(20)30296-0]Langman-LevyA , JohnsL , Palmier-ClausJ , SacaduraC , SteeleA , LarkinA , et al. Adapting cognitive behavioural therapy for adolescents with psychosis: insights from the Managing Adolescent first episode in psychosis study (MAPS). Psychosis: Psychological, Social and Integrative Approaches2023;15(1):28-43. [DOI: 10.1080/17522439.2021.2001561]MorrisonAP , PyleM , MaughanD , JohnsL , FreemanD , BroomeMR , et al. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. The Lancet Psychiatry2020;7(9):788-800. [DOI: 10.1016/ S2215-0366(20)30248-0]Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. Health Technology Assessment2021;25(4):1-152. [DOI: 10.3310/hta25040]PyleM , BroomeMR , JoyceE , MacLennanG , NorrieJ , FreemanD , et al. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials2019;20(397):1-13. [DOI: 10.1186/s13063-019-3506-1]">Morrison 2020 – MAPS</a>), feasibility and effectiveness (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>), or to determine non‐inferiority of CBT without antipsychotic medication to standard care (<a href="./references#CD015332-bbs2-0001" title="ACTRN12607000608460. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression to evaluate the impact on functioning and symptomatology. The STAGES Study: Staged Treatment and Acceptability Guidelines in Early Psychosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&amp;isReview=true (first received 26 November 2007). FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O’DonoghueB , et al. Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio. Early Intervention in Psychiatry2018;12(S1):70. FranceySM , NelsonB , BechdolfA , ThompsonA , FraserR , HarriganS , et al. A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Intervention in Psychiatry2008;2:Spp 1 (20). FranceySM , NelsonB , HarriganS , KerrM , SpiliotacopoulosD , MacneilC , et al. Should antipsychotic medication always be given for first episode psychosis?Early Intervention in Psychiatry2012;6(S1):96. FranceySM , O’DonoghueB , NelsonB , GrahamJ , BaldwinL , YuenHP , et al. Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial. Schizophrenia Bulletin Open2020;1(1):1-11. [DOI: 10.1093/schizbullopen/sgaa015]O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahamJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry2019;13(4):953-960. [DOI: 10.1111/eip.12716]">Francey 2020 – STAGES</a>). Studies designed to investigate the efficacy of this approach would probably require a different sample size calculation. </p> </section> <section id="CD015332-sec-0220"> <h3 class="title" id="CD015332-sec-0220">Quality of the evidence</h3> <p>We assessed the certainty of the evidence as very low to low using the GRADE approach.</p> <p>For all outcomes evaluated in comparison 1, CBT without antipsychotics compared to standard care without antipsychotics, we evaluated the certainty of the evidence as low due to inadequate information size and imprecise results. </p> <p>For all outcomes evaluated in comparison 2, CBT without antipsychotics compared to standard care including antipsychotics, we evaluated the certainty of the evidence as very low due to high risk of bias, inadequate information size, and imprecise results. Only for the outcome 'participants with at least one adverse event' were results not imprecise, favouring CBT without antipsychotics, but the certainty of the evidence was still very low due to high risk of bias and the very low number of participants. </p> <p>For all outcomes evaluated in comparison 3, CBT without antipsychotics compared to CBT in combination with antipsychotics, we evaluated the certainty of the evidence as very low because the majority of the studies contributing to this outcome were at high risk of bias; information size was inadequate; and results were imprecise. For the outcome 'participants with at least one adverse event', there was also substantial heterogeneity between results from the various studies providing data. </p> </section> <section id="CD015332-sec-0221"> <h3 class="title" id="CD015332-sec-0221">Potential biases in the review process</h3> <p>We have documented and justified modifications to our published protocol in the <a href="#CD015332-sec-0235">Differences between protocol and review</a> section. </p> <p>The current review has some limitations.</p> <p>Firstly, the search is about a year and a half old. However, due to the very special topic investigated and thanks to communications with the authors of the included studies, we doubt that any new eligible studies would have been published in the meantime. On the other hand, it must be noted that the search was very broad, retrieving all the references where the term "cognit" was used, thereby minimising the risk of missing potentially relevant studies. </p> <p>Secondly, we were unable to conduct any subgroup analyses to investigate potential moderators, since all analyses included a maximum of one to three studies. For the same reason, it was not possible to conduct sensitivity analyses exploring the influence of factors such as risk of bias. </p> </section> <section id="CD015332-sec-0222"> <h3 class="title" id="CD015332-sec-0222">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of previous systematic reviews that have attempted to synthesise the evidence on this specific topic. </p> <p>Existing evidence is available about CBT when delivered in addition to standard care, meaning implicitly in combination with antipsychotics. These reviews have shown efficacy for multiple symptoms (<a href="./references#CD015332-bbs2-0014" title="BighelliI , SalantiG , HuhnM , Schneider-ThomaJ , KrauseM , ReitmeirC , et al. Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. World Psychiatry2018;17(3):316-29.">Bighelli 2018</a>; <a href="./references#CD015332-bbs2-0038" title="JauharS , McKennaPJ , RaduaJ , FungE , SalvadorR , LawsKR . Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry2014;204:20-9. [DOI: 10.1192/bjp.bp.112.116285]">Jauhar 2014</a>; <a href="./references#CD015332-bbs2-0039" title="JonesC , HackerD , MeadenA , CormacI , IrvingCB , XiaJ , et al. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: CD008712. [DOI: 10.1002/14651858.CD008712.pub3]">Jones 2018a</a>; <a href="./references#CD015332-bbs2-0040" title="JonesC , HackerD , XiaJ , MeadenA , IrvingCB , ZhaoS , et al. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD007964. [DOI: 10.1002/14651858.CD007964.pub2]">Jones 2018b</a>). </p> <p>In randomised trials investigating CBT included in previous reviews, the dose or type of antipsychotic medication provided is rarely specified in detail, so that it is not possible to investigate its role with, for example, meta‐regression analyses. </p> <p>An exploratory trial by Morrison and colleagues examined 20 participants with schizophrenia receiving cognitive therapy who had not been taking antipsychotic medication for at least six months (<a href="./references#CD015332-bbs2-0062" title="MorrisonAP , HuttonP , WardleM , SpencerH , BarrattS , BrabbanA , et al. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychological Medicine2012;42:1049-56. [DOI: 10.1017/S0033291711001899]">Morrison 2012b</a>). Post‐treatment scores showed a reduction in symptoms measured by the PANSS and an improvement in functioning, both at post‐treatment and follow‐up. Only three participants had an increase in PANSS scores, but without reaching a clinically significant deterioration. Despite the limitations connected to the open and non‐randomised design, the authors concluded that cognitive therapy without antipsychotics is acceptable, and conducted a randomised trial to further test this hypothesis (<a href="./references#CD015332-bbs2-0002" title="ConusP , FranceyS , O’DonoghueB , MorrisonAP . Management of psychosis without the use of antipsychotic medication. Early Intervention In Psychiatry2016;10(S1):8. [DOI: 10.1111/eip.12395]HowesO . Cognitive therapy: at last an alternative to antipsychotics?Lancet2014;383(9926):1364-1366. [DOI: 10.1016/ S0140-6736(13)62569-6]HuttonP , Di RienzoF , TurkingtonD , SpencerH , TaylorP . Suicidal ideation in people with psychosis not taking antipsychotic medication: do negative appraisals and negative metacognitive beliefs mediate the effect of symptoms?Schizophrenia Bulletin2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]ISRCTN29607432. Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial. www.isrctn.com/ISRCTN296074322010. [DOI: 10.1186/ISRCTN29607432]MorrisonA . Psychological interventions for promoting recovery. European Archives of Psychiatry and Clinical Neuroscience2017;267:S7-S8. [DOI: 10.1007/s00406-017-0824-8]MorrisonAP , TurkingtonD , PyleM , SpencerH , BrabbanA , DunnG , et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet2014;383(9926):1395-403. [DOI: 10.1016/ S0140-6736(13)62246-1]MorrisonAP , WardleM , HuttonP , DaviesL , DunnG , BrabbanA , et al. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. Psychosis: Psychological, Social and Integrative Approaches2013;5(1):82-92. [DOI: 10.1080/17522439.2012.756539]SpencerHM , McMenaminM , EmsleyR , TurkingtonD , DunnG , MorrisonAP , et al. Cognitive behavioral therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?Schizophrenia Research2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]TorjesenI . CBT could benefit patients with schizophrenia who do not take medication, research says. BMJ2014;348:1. [DOI: 10.1136/bmj.g1417]">Morrison 2014 – ACTION</a>). Results of the current systematic review also did not find a difference between CBT without antipsychotics and control conditions in terms of number of participants with relapse or deterioration of symptoms. This approach might therefore be safely further investigated in future trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015332-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD015332-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 1: Mental state – general: mean endpoint PANSS total (high = poor)" data-id="CD015332-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 1: Mental state – general: mean endpoint PANSS total (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 2: Number of participants with clinically important change in general mental state (separated time points)" data-id="CD015332-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 2: Number of participants with clinically important change in general mental state (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 3: Mental state – specific: mean endpoint PANSS positive (high = poor)" data-id="CD015332-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 3: Mental state – specific: mean endpoint PANSS positive (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 4: Mental state – specific: mean endpoint PANSS negative (high = poor)" data-id="CD015332-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 4: Mental state – specific: mean endpoint PANSS negative (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 5: Mental state – specific: mean endpoint BDI (high = poor)" data-id="CD015332-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 5: Mental state – specific: mean endpoint BDI (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 6: Mental state – specific: mean endpoint BAI (high = poor)" data-id="CD015332-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 6: Mental state – specific: mean endpoint BAI (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 7: Global state – number of participants with relapse/exacerbations of psychosis (separated time points)" data-id="CD015332-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 7: Global state – number of participants with relapse/exacerbations of psychosis (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 8: Service use – readmission to hospital" data-id="CD015332-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 8: Service use – readmission to hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 9: Service use – mean number of days in hospital" data-id="CD015332-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 9: Service use – mean number of days in hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 10: Leaving the study early – for any reason – overall acceptability (separated time points)" data-id="CD015332-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 10: Leaving the study early – for any reason – overall acceptability (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 11: Functioning – mean endpoint PSP (high = good)" data-id="CD015332-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 11: Functioning – mean endpoint PSP (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 12: Behaviour – participants with suicide attempts" data-id="CD015332-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 12: Behaviour – participants with suicide attempts </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 13: Adverse events – deterioration of symptoms" data-id="CD015332-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 13: Adverse events – deterioration of symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 14: Adverse events – participants with serious adverse events" data-id="CD015332-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 14: Adverse events – participants with serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 15: Mortality – overall mortality" data-id="CD015332-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 15: Mortality – overall mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: CBT versus no specific treatment, Outcome 16: Mortality – mortality due to natural causes" data-id="CD015332-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: CBT versus no specific treatment, Outcome 16: Mortality – mortality due to natural causes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 1: Mental state – general: mean endpoint PANSS total (high = poor)" data-id="CD015332-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 1: Mental state – general: mean endpoint PANSS total (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 2: Number of participants with clinically important change in general mental state (separated time points)" data-id="CD015332-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 2: Number of participants with clinically important change in general mental state (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 3: Mental state – specific: mean endpoint PANSS positive (high = poor)" data-id="CD015332-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 3: Mental state – specific: mean endpoint PANSS positive (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 4: Mental state – specific: mean endpoint PANSS negative (high = poor)" data-id="CD015332-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 4: Mental state – specific: mean endpoint PANSS negative (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 5: Mental state – specific: mean endpoint HADS Depression (high = poor)" data-id="CD015332-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 5: Mental state – specific: mean endpoint HADS Depression (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 6: Mental state – specific: mean endpoint HADS Anxiety (high = poor)" data-id="CD015332-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 6: Mental state – specific: mean endpoint HADS Anxiety (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 7: Global state – number of participants with relapse/exacerbations of psychosis (separated time points)" data-id="CD015332-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 7: Global state – number of participants with relapse/exacerbations of psychosis (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 8: Global state – mean endpoint CGI‐Clinician (high = poor)" data-id="CD015332-fig-0025" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 8: Global state – mean endpoint CGI‐Clinician (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 9: Global state – mean endpoint CGI‐Clinician – Improvement (high = poor)" data-id="CD015332-fig-0026" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 9: Global state – mean endpoint CGI‐Clinician – Improvement (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 10: Service use – readmission to hospital" data-id="CD015332-fig-0027" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 10: Service use – readmission to hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 11: Service use – number of days in hospital (separated time points)" data-id="CD015332-fig-0028" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 11: Service use – number of days in hospital (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 12: Leaving the study early – for any reason – overall acceptability (separated time points)" data-id="CD015332-fig-0029" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 12: Leaving the study early – for any reason – overall acceptability (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 13: Functioning – mean endpoint PSP (high = good)" data-id="CD015332-fig-0030" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 13: Functioning – mean endpoint PSP (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 14: Functioning – mean endpoint FESFS (high = good)" data-id="CD015332-fig-0031" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 14: Functioning – mean endpoint FESFS (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 15: Functioning – mean endpoint functioning scales (high = good)" data-id="CD015332-fig-0032" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 15: Functioning – mean endpoint functioning scales (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 16: Quality of life – mean endpoint WHOQOL (high = good)" data-id="CD015332-fig-0033" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 16: Quality of life – mean endpoint WHOQOL (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 17: Quality of life – mean endpoint EQ‐5D‐5L (high = good)" data-id="CD015332-fig-0034" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 17: Quality of life – mean endpoint EQ‐5D‐5L (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 18: Quality of life – mean endpoint quality of life scales (high = good)" data-id="CD015332-fig-0035" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 18: Quality of life – mean endpoint quality of life scales (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 19: Behaviour – violent incidents (separated time points)" data-id="CD015332-fig-0036" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 19: Behaviour – violent incidents (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 20: Behaviour – self‐injury (separated time points)" data-id="CD015332-fig-0037" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 20: Behaviour – self‐injury (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 21: Behaviour – suicide attempts (separated time points)" data-id="CD015332-fig-0038" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 21: Behaviour – suicide attempts (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 22: Adverse events – participants with at least 1 adverse event" data-id="CD015332-fig-0039" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 22: Adverse events – participants with at least 1 adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 23: Adverse events – participants with serious adverse events" data-id="CD015332-fig-0040" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 23: Adverse events – participants with serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 24: Adverse events – deterioration of symptoms" data-id="CD015332-fig-0041" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 24: Adverse events – deterioration of symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-002.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: CBT versus antipsychotics, Outcome 25: Adverse events – mean endpoint ANNSERS (high = poor)" data-id="CD015332-fig-0042" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-002.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2: CBT versus antipsychotics, Outcome 25: Adverse events – mean endpoint ANNSERS (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-002.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 1: Mental state – general: mean endpoint PANSS total (high = poor)" data-id="CD015332-fig-0043" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 1: Mental state – general: mean endpoint PANSS total (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 2: Mental state – general: mean endpoint BPRS total (high = poor)" data-id="CD015332-fig-0044" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 2: Mental state – general: mean endpoint BPRS total (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 3: Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)" data-id="CD015332-fig-0045" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 3: Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 4: Mental state – general: number of participants with clinically important change in general mental state (separated time points)" data-id="CD015332-fig-0046" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 4: Mental state – general: number of participants with clinically important change in general mental state (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 5: Mental state – specific: mean endpoint PANSS positive (high = poor)" data-id="CD015332-fig-0047" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 5: Mental state – specific: mean endpoint PANSS positive (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 6: Mental state – specific: mean endpoint BPRS positive (high = poor)" data-id="CD015332-fig-0048" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 6: Mental state – specific: mean endpoint BPRS positive (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 7: Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points)" data-id="CD015332-fig-0049" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 7: Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 8: Mental state – specific: mean endpoint PANSS negative (high = poor)" data-id="CD015332-fig-0050" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 8: Mental state – specific: mean endpoint PANSS negative (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 9: Mental state – specific: mean endpoint SANS negative (high = poor)" data-id="CD015332-fig-0051" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 9: Mental state – specific: mean endpoint SANS negative (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 10: Mental state – specific: mean endpoint negative symptoms scales (high = poor)" data-id="CD015332-fig-0052" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 10: Mental state – specific: mean endpoint negative symptoms scales (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 11: Mental state – specific: mean endpoint HADS Depression (high = poor)" data-id="CD015332-fig-0053" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 11: Mental state – specific: mean endpoint HADS Depression (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 12: Mental state – specific: mean endpoint HAM‐D (high = poor)" data-id="CD015332-fig-0054" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 12: Mental state – specific: mean endpoint HAM‐D (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 13: Mental state – specific: mean endpoint depression scales (high = poor)" data-id="CD015332-fig-0055" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 13: Mental state – specific: mean endpoint depression scales (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 14: Mental state – specific: mean endpoint HADS Anxiety (high = poor)" data-id="CD015332-fig-0056" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 14: Mental state – specific: mean endpoint HADS Anxiety (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 15: Mental state – specific: mean endpoint HAM‐A (high = poor)" data-id="CD015332-fig-0057" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 15: Mental state – specific: mean endpoint HAM‐A (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 16: Mental state – specific: mean endpoint anxiety scales (high = poor)" data-id="CD015332-fig-0058" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 16: Mental state – specific: mean endpoint anxiety scales (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 17: Global state – number of participants with relapse/exacerbations of psychosis (separated time points)" data-id="CD015332-fig-0059" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 17: Global state – number of participants with relapse/exacerbations of psychosis (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 18: Global state – mean endpoint CGI‐Clinician (high = poor)" data-id="CD015332-fig-0060" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 18: Global state – mean endpoint CGI‐Clinician (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 19: Global state – mean endpoint CGI‐Clinician – Improvement (high = poor)" data-id="CD015332-fig-0061" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 19: Global state – mean endpoint CGI‐Clinician – Improvement (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 20: Service use – readmission to hospital (separated time points)" data-id="CD015332-fig-0062" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 20: Service use – readmission to hospital (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 21: Service use – number of days in hospital (separated time points)" data-id="CD015332-fig-0063" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 21: Service use – number of days in hospital (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 22: Leaving the study early – for any reason – overall acceptability (separated time points)" data-id="CD015332-fig-0064" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 22: Leaving the study early – for any reason – overall acceptability (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 23: Leaving the study early due to adverse effects (separated time points)" data-id="CD015332-fig-0065" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 23: Leaving the study early due to adverse effects (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 24: Functioning – mean endpoint PSP (high = good)" data-id="CD015332-fig-0066" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 24: Functioning – mean endpoint PSP (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 25: Functioning – mean endpoint FESFS (high = good)" data-id="CD015332-fig-0067" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 25: Functioning – mean endpoint FESFS (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 26: Functioning – mean endpoint SOFAS (high = good)" data-id="CD015332-fig-0068" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 26: Functioning – mean endpoint SOFAS (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 27: Functioning – mean endpoint functioning scales (high = good)" data-id="CD015332-fig-0069" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 27: Functioning – mean endpoint functioning scales (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 28: Quality of life – mean endpoint WHOQOL (high = good)" data-id="CD015332-fig-0070" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 28: Quality of life – mean endpoint WHOQOL (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 29: Quality of life – mean endpoint EQ‐5D‐5L (high = good)" data-id="CD015332-fig-0071" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 29: Quality of life – mean endpoint EQ‐5D‐5L (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 30: Quality of life – mean endpoint Quality of Life Scale (high = good)" data-id="CD015332-fig-0072" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 30: Quality of life – mean endpoint Quality of Life Scale (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 31: Quality of life – mean endpoint quality of life scales (high = good)" data-id="CD015332-fig-0073" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 31: Quality of life – mean endpoint quality of life scales (high = good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 32: Behaviour – violent incidents (separated time points)" data-id="CD015332-fig-0074" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.32</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 32: Behaviour – violent incidents (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 33: Behaviour – self‐injury (separated time points)" data-id="CD015332-fig-0075" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.33</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 33: Behaviour – self‐injury (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 34: Behaviour – suicide attempts (separated time points)" data-id="CD015332-fig-0076" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.34</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 34: Behaviour – suicide attempts (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 35: Adverse events – participants with at least 1 adverse event (pooled time points)" data-id="CD015332-fig-0077" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.35</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 35: Adverse events – participants with at least 1 adverse event (pooled time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 36: Adverse events – participants with at least 1 adverse event (separated time points)" data-id="CD015332-fig-0078" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.36</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 36: Adverse events – participants with at least 1 adverse event (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 37: Adverse events – participants with serious adverse events (separated time points)" data-id="CD015332-fig-0079" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.37</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 37: Adverse events – participants with serious adverse events (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 38: Adverse events – deterioration of symptoms (separated time points)" data-id="CD015332-fig-0080" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.38</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 38: Adverse events – deterioration of symptoms (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 39: Adverse events – lack of improvement (separated time points)" data-id="CD015332-fig-0081" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.39</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 39: Adverse events – lack of improvement (separated time points) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 40: Adverse events – mean endpoint ANNSERS (high = poor)" data-id="CD015332-fig-0082" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.40</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 40: Adverse events – mean endpoint ANNSERS (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015332-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/urn:x-wiley:14651858:media:CD015332:CD015332-CMP-003.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: CBT versus CBT plus antipsychotics, Outcome 41: Adverse events – mean endpoint UKU (high = poor)" data-id="CD015332-fig-0083" src="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_t/tCD015332-CMP-003.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.41</div> <div class="figure-caption"> <p>Comparison 3: CBT versus CBT plus antipsychotics, Outcome 41: Adverse events – mean endpoint UKU (high = poor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/media/CDSR/CD015332/image_n/nCD015332-CMP-003.41.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015332-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to no specific treatment for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBT without antipsychotics compared to no specific treatment for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> <br/><b>Intervention:</b> CBT without antipsychotics<br/><b>Comparison:</b> no specific treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no specific treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT without antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ general: mean endpoint PANSS total (high = poor) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>9.77 lower</b><br/>(20.59 lower to 1.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ &gt; 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(3 to 285) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.05 to 5.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/>(31 to 372) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.23 to 2.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functioning ‐ mean endpoint PSP (high = good) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>12.42 lower</b><br/>(22.75 lower to 2.09 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Participants with at least one AE ‐ &gt; 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_439003076253823530" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_439003076253823530</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI includes both better outcome for CBT without antipsychotics and almost no difference<br/><sup>b</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) and CI includes both better outcome for CBT without antipsychotics and better outcome for standard care without antipsychotics </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to no specific treatment for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015332-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBT without antipsychotics compared to antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> <br/><b>Intervention:</b> CBT without antipsychotics<br/><b>Comparison:</b> antipsychotics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antipsychotics</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT without antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ general: mean endpoint PANSS total (high = poor) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>3.38 higher</b><br/>(2.38 lower to 9.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.78</b><br/>(0.12 to 65.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/>(5 to 281) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.66</b><br/>(0.21 to 12.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functioning ‐ mean endpoint functioning scales (high = good) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.03 lower</b><br/>(0.61 lower to 0.55 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Participants with at least one AE (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>591 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b><br/>(124 to 632) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b><br/>(0.21 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842958834426261" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842958834426261</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for risk of bias: two out of two studies were at overall high risk of bias<br/><sup>b</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI includes both better outcome for CBT without antipsychotics and better outcome for standard care<br/><sup>c</sup> Downgraded by two levels for risk of bias: one out of one study was at overall high risk of bias<br/><sup>d</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) and CI includes both better outcome for CBT without antipsychotics and better outcome for standard care<br/><sup>e</sup> Downgraded by one level for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to antipsychotics for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015332-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to CBT plus antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBT without antipsychotics compared to CBT plus antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> <br/><b>Intervention:</b> CBT without antipsychotics<br/><b>Comparison:</b> CBT plus antipsychotics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT plus antipsychotics</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with CBT without antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.3 higher</b><br/>(0.06 lower to 0.65 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.89</b><br/>(0.12 to 67.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/>(8 to 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b><br/>(0.12 to 4.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Functioning ‐ mean endpoint functioning scales (high = good) ‐ &lt; 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.13 higher</b><br/>(0.25 lower to 0.5 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Participants with at least one AE (separated time points) ‐ &lt; 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b><br/>(130 to 610) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b><br/>(0.17 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842947953353100" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_438842947953353100</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for risk of bias: two out of three studies were at overall high risk of bias<br/><sup>b</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI includes both no difference and better outcome for CBT plus antipsychotics<br/><sup>c</sup> Downgraded by two levels for risk of bias: one out of one study was at overall high risk of bias<br/><sup>d</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome) and CI includes both no difference and better outcome for CBT plus antipsychotics<br/><sup>e</sup> Downgraded by two levels for risk of bias: two out of two studies were at overall high risk of bias<br/><sup>f</sup> Downgraded by one level for imprecision: inadequate information size (&lt; 1000 participants for a dichotomous outcome)<br/><sup>g</sup> Downgraded by two levels for imprecision: inadequate information size (&lt; 800 participants for a continuous outcome) and CI ranges from better outcome with CBT without antipsychotics to better outcome with CBT plus antipsychotics<br/><sup>h</sup> Downgraded by one level for risk of bias: the study is at overall high risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ CBT without antipsychotics compared to CBT plus antipsychotics for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015332-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Numbers of participants receiving antipsychotic medication during the trial</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CBT</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CBT plus antipsychotics</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Antipsychotics</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No specific treatment</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Francey 2020 – STAGES</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/41 (46.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morrison 2018 – COMPARE</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/26 (30.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/25 (72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/24 (66.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morrison 2020 – MAPS</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/18 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/21 (57.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/22 (72.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morrison 2014 – ACTION</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/37 (27%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/37 (27%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CBT: cognitive behavioural therapy</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Numbers of participants receiving antipsychotic medication during the trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/full#CD015332-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015332-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CBT versus no specific treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mental state – general: mean endpoint PANSS total (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.99 [‐14.91, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.77 [‐20.59, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.77 [‐27.75, ‐1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Number of participants with clinically important change in general mental state (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.65, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.65, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mental state – specific: mean endpoint PANSS positive (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐4.23, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐6.52, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐8.56, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Mental state – specific: mean endpoint PANSS negative (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐3.72, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.34 [‐6.53, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.06 [‐7.50, ‐0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mental state – specific: mean endpoint BDI (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐2.80, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐2.94, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.88 [‐5.62, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mental state – specific: mean endpoint BAI (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.15 [‐13.34, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.86 [‐25.61, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.75 [‐26.32, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Global state – number of participants with relapse/exacerbations of psychosis (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Service use – readmission to hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.27, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Service use – mean number of days in hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.45 [‐28.82, ‐16.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Leaving the study early – for any reason – overall acceptability (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.32, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.23, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.52, 12.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Functioning – mean endpoint PSP (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.85 [‐18.13, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.42 [‐22.75, ‐2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.80 [‐21.86, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Behaviour – participants with suicide attempts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Adverse events – deterioration of symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.15, 6.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Adverse events – participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Mortality – overall mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Mortality – mortality due to natural causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CBT versus no specific treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015332-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CBT versus antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mental state – general: mean endpoint PANSS total (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.75 [‐11.61, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.38 [‐2.38, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Number of participants with clinically important change in general mental state (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.44, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.36, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mental state – specific: mean endpoint PANSS positive (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐3.08, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [‐2.80, 6.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Mental state – specific: mean endpoint PANSS negative (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.19 [‐5.27, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [‐2.63, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Mental state – specific: mean endpoint HADS Depression (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.75 [‐4.27, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐3.08, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Mental state – specific: mean endpoint HADS Anxiety (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐4.02, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐3.77, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Global state – number of participants with relapse/exacerbations of psychosis (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [0.36, 15.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.12, 65.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Global state – mean endpoint CGI‐Clinician (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.49, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.50, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Global state – mean endpoint CGI‐Clinician – Improvement (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.89, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.57, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Service use – readmission to hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.48 [0.35, 119.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Service use – number of days in hospital (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Leaving the study early – for any reason – overall acceptability (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.21, 12.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.21, 12.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Functioning – mean endpoint PSP (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [‐5.00, 12.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐9.70, 8.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Functioning – mean endpoint FESFS (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐6.03, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐8.46, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Functioning – mean endpoint functioning scales (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.37, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.61, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Quality of life – mean endpoint WHOQOL (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐10.98, 10.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.45 [‐13.05, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Quality of life – mean endpoint EQ‐5D‐5L (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.18, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.24, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Quality of life – mean endpoint quality of life scales (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.42, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.64, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Behaviour – violent incidents (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.19, 7.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Behaviour – self‐injury (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.43, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Behaviour – suicide attempts (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [0.16, 84.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Adverse events – participants with at least 1 adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.21, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Adverse events – participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.80, 10.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Adverse events – deterioration of symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.41, 11.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.04, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.25 Adverse events – mean endpoint ANNSERS (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.94 [‐8.60, ‐1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.96 [‐11.55, ‐2.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CBT versus antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015332-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CBT versus CBT plus antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mental state – general: mean endpoint PANSS total (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [‐5.41, 11.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [‐3.89, 8.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Mental state – general: mean endpoint BPRS total (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐5.10, 7.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.40 [‐0.82, 9.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐3.35, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.21, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.06, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.32, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Mental state – general: number of participants with clinically important change in general mental state (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.33, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Mental state – specific: mean endpoint PANSS positive (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.21, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [‐1.16, 6.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Mental state – specific: mean endpoint BPRS positive (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐2.38, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [‐0.28, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐1.19, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.19, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.05, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Mental state – specific: mean endpoint PANSS negative (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [‐4.42, 5.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [‐1.36, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Mental state – specific: mean endpoint SANS negative (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐6.32, 8.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [1.98, 13.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐3.55, 8.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Mental state – specific: mean endpoint negative symptoms scales (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.36, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.01, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Mental state – specific: mean endpoint HADS Depression (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [‐1.55, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐2.86, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Mental state – specific: mean endpoint HAM‐D (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐2.82, 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐0.77, 6.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐1.53, 6.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Mental state – specific: mean endpoint depression scales (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.18, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.22, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Mental state – specific: mean endpoint HADS Anxiety (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [‐4.54, 5.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [‐1.44, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Mental state – specific: mean endpoint HAM‐A (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐5.93, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [‐2.78, 5.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐2.93, 7.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Mental state – specific: mean endpoint anxiety scales (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.37, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.17, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.31, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Global state – number of participants with relapse/exacerbations of psychosis (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.30, 16.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.12, 67.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 Global state – mean endpoint CGI‐Clinician (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [‐0.00, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐0.28, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.19 Global state – mean endpoint CGI‐Clinician – Improvement (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.1 &lt; 6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [‐0.00, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.2 &lt; 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.41, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.20 Service use – readmission to hospital (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.02, 8.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.12, 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.21 Service use – number of days in hospital (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.75 [‐26.53, 42.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.22 Leaving the study early – for any reason – overall acceptability (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.59, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.12, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.23 Leaving the study early due to adverse effects (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.24 Functioning – mean endpoint PSP (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [‐6.24, 11.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐9.04, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.25 Functioning – mean endpoint FESFS (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐5.38, 6.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐7.87, 5.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.26 Functioning – mean endpoint SOFAS (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐7.29, 6.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [‐4.04, 11.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [‐4.08, 12.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.27 Functioning – mean endpoint functioning scales (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.30, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.25, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐0.27, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.28 Quality of life – mean endpoint WHOQOL (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.90 [‐0.68, 20.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐12.57, 10.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.29 Quality of life – mean endpoint EQ‐5D‐5L (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.04, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.27, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.30 Quality of life – mean endpoint Quality of Life Scale (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐11.28, 13.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.50 [‐4.65, 19.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [‐8.67, 15.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.31 Quality of life – mean endpoint quality of life scales (high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [‐0.11, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.21, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.3 &gt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.40, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.32 Behaviour – violent incidents (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.18, 7.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.33 Behaviour – self‐injury (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.30, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.26, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.34 Behaviour – suicide attempts (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34.1 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.08, 17.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.35 Adverse events – participants with at least 1 adverse event (pooled time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.23, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.36 Adverse events – participants with at least 1 adverse event (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.36.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.78, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.36.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.17, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.37 Adverse events – participants with serious adverse events (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.37.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.37, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.37.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.32, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.38 Adverse events – deterioration of symptoms (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.38.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.37, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.38.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.11, 9.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.39 Adverse events – lack of improvement (separated time points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.39.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.33, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.40 Adverse events – mean endpoint ANNSERS (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.40.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.68 [‐9.66, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.40.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.47 [‐12.06, 5.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.41 Adverse events – mean endpoint UKU (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.41.1 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.86 [‐6.37, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.41.2 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.47 [‐12.06, 5.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CBT versus CBT plus antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#CD015332-tbl-0007">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Mental state – general: mean endpoint PANSS total (high = poor)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.3 &gt; 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Mental state – general: mean endpoint PANSS total (high = poor)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Global state – number of participants with relapse/exacerbations of psychosis (separated time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.1 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.2 &gt; 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Global state – number of participants with relapse/exacerbations of psychosis (separated time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Leaving the study early – for any reason – overall acceptability (separated time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.3 &gt; 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Leaving the study early – for any reason – overall acceptability (separated time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Functioning – mean endpoint PSP (high = good)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.3 &gt; 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2014 – ACTION</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions, but these are equally distributed in the two groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Functioning – mean endpoint PSP (high = good)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Mental state – general: mean endpoint PANSS total (high = poor)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Mental state – general: mean endpoint PANSS total (high = poor)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Global state – number of participants with relapse/exacerbations of psychosis (separated time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.7.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.7.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Global state – number of participants with relapse/exacerbations of psychosis (separated time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.12 Leaving the study early – for any reason – overall acceptability (separated time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.12.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.12.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.12 Leaving the study early – for any reason – overall acceptability (separated time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.15 Functioning – mean endpoint functioning scales (high = good)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.15.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.15.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.15 Functioning – mean endpoint functioning scales (high = good)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.22 Adverse events – participants with at least 1 adverse event</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.22.1 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.22 Adverse events – participants with at least 1 adverse event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is mentioned in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is mentioned in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.3.3 &gt; 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is mentioned in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.17 Global state – number of participants with relapse/exacerbations of psychosis (separated time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.17.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.17.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.17 Global state – number of participants with relapse/exacerbations of psychosis (separated time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.22 Leaving the study early – for any reason – overall acceptability (separated time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.22.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.22.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not mentioned in the trial registration, but according to CONSORT is expected to be reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.22 Leaving the study early – for any reason – overall acceptability (separated time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.27 Functioning – mean endpoint functioning scales (high = good)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.27.1 &lt; 6 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.27.2 &lt; 12 months</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2018 – COMPARE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are not available for more than 20% of the participants; it is not excluded that missingness of the outcome might be related to participants’ health status. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.27.3 &gt; 1 year</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.27 Functioning – mean endpoint functioning scales (high = good)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.35 Adverse events – participants with at least 1 adverse event (pooled time points)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Francey 2020 – STAGES</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinicians, research staff and participants are blind; intention to treat analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the protocol of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> <tr class="study-data"> <td> <p>Morrison 2020 – MAPS</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised. Randomisation was independent and concealed. No baseline difference to suggest a problem with the randomisation process </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and therapists are not blind; there are deviations from intended interventions not balanced between the groups; ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on this outcome are available for nearly all randomised participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was measured with a valid method by blind outcome assessors</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registration of this study.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Calculated based on RoB2 algorithm.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.35 Adverse events – participants with at least 1 adverse event (pooled time points)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015332.pub2/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015332.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015332-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015332-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015332-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015332-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD015332-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD015332-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015332-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD015332-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD015332-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015332-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015332-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015332\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015332\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015332\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015332\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015332\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015332.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015332.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015332.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015332.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015332.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726911071"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015332.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726911075"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015332.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9f2b7e28f480',t:'MTc0MDcyNjkxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 